Dex Liquidating (CRDC) 10-K 25 Sep 14 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Jun. 30, 2014	Sep. 18, 2014	Dec. 31, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'CARDICA INC	'	'
Document Type	'10-K	'	'
Current Fiscal Year End Date	'--06-30	'	'
Entity Common Stock, Shares Outstanding	'	88,951,216	'
Entity Public Float	'	'	$31,888,386
Amendment Flag	'false	'	'
Entity Central Index Key	'0001178104	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Document Period End Date	30-Jun-14	'	'
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'FY	'	'

Balance_Sheets

Balance Sheets (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$5,395	$6,373
Short-term investments	35,086	6,022
Accounts receivable, net of allowance of $0 and $33	706	391
Inventories	1,086	1,457
Prepaid expenses and other current assets	349	253
Total current assets	42,622	14,496
Property and equipment, net	2,536	3,161
Long-term investments	2,315	'
Restricted cash	104	104
Total assets	47,577	17,761
Current liabilities	'	'
Accounts payable	847	764
Accrued compensation	899	600
Other accrued liabilities	437	420
Current portion of deferred rent	71	'
Current portion of deferred revenue	403	444
Total current liabilities	2,657	2,228
Deferred revenue, net of current portion	1,610	1,610
Note payable	3,092	2,788
Other non-current liabilities	33	161
Total liabilities	7,392	6,787
Commitments and contingencies (Note 5)	'	'
Stockholders’ equity	'	'
Preferred stock, $0.001 par value: 5,000,000 shares authorized at June 30, 2014 and 2013, 191,474 and 0 shares issued and outstanding at June 30, 2014 and 2013, respectively	17,214	'
Common stock, $0.001 par value: 125,000,000 and 75,000,000 shares authorized; 89,005,443 and 51,068,614 shares issued and 88,939,216 and 51,002,387 shares outstanding at June 30, 2014 and 2013, respectively	89	51
Additional paid-in capital	194,015	165,085
Treasury stock at cost (66,227 shares at June 30, 2014 and 2013)	-596	-596
Accumulated other comprehensive loss	-10	-5
Accumulated deficit	-170,527	-153,561
Total stockholders’ equity	40,185	10,974
Total liabilities and stockholders’ equity	$47,577	$17,761

Balance_Sheets_Parentheticals

Balance Sheets (Parentheticals) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, except Share data, unless otherwise specified
Accounts receivable, allowance (in Dollars)	$0	$33
Preferred stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	191,474	0
Preferred stock, shares outstanding	191,474	0
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized	125,000,000	75,000,000
Common stock, shares issued	89,005,443	51,068,614
Common stock, shares outstanding	88,939,216	51,002,387
Treasury stock shares	66,227	66,227

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Net revenue	'	'	'
Product sales, net	$3,505	$3,093	$3,274
License and development revenue	41	336	336
Royalty revenue	69	70	71
Total net revenue	3,615	3,499	3,681
Operating costs and expenses	'	'	'
Cost of product sales	4,770	3,604	3,638
Research and development	6,883	9,145	7,220
Selling, general and administrative	8,463	6,410	6,139
Total operating costs and expenses	20,116	19,159	16,997
Loss from operations	-16,501	-15,660	-13,316
Interest income	12	15	12
Interest expense	-504	-457	-268
Other income (expense), net	27	-35	-3
Net loss before income tax	-16,966	-16,137	-13,575
Income tax benefit	0	0	0
Net loss	-16,966	-16,137	-13,575
Deemed dividend related to beneficial conversion feature of convertible preferred stock	-1,915	'	'
Net loss allocable to common stockholders	($18,881)	($16,137)	($13,575)
Basic and diluted net loss per share allocable to common stockholders (in Dollars per share)	($0.32)	($0.40)	($0.44)
Shares used in computing basic and diluted net loss per share allocable to common stockholders (in Shares)	58,395	40,842	30,547

Statements_of_Comprehensive_Lo

Statements of Comprehensive Loss (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Net loss	($16,966)	($16,137)	($13,575)
Other comprehensive loss:	'	'	'
Change in unrealized loss on investment	-5	'	-4
Comprehensive loss	($16,971)	($16,137)	($13,579)

Statements_of_Stockholders_Equ

Statements of Stockholders' Equity (USD $)

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Treasury Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Member]

Retained Earnings [Member]

Wedbush [Member]

MLV [Member]

Total

Preferred Stock [Member]

USD ($)

Wedbush [Member]

Aspire [Member]

MLV [Member]

USD ($)

Wedbush [Member]

MLV [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Balance at June 30 at Jun. 30, 2011

'

'

'

'

'

$27,000

'

'

$133,281,000

($596,000)

($1,000)

($123,849,000)

'

'

$8,862,000

Balance at June 30 (in Shares) at Jun. 30, 2011

'

'

'

'

'

26,635,115

'

'

'

'

'

'

'

'

'

Issuance of common stock upon exercise of employee stock options for cash

'

'

'

'

'

'

'

'

134,000

'

'

'

'

'

134,000

Issuance of common stock upon exercise of employee stock options for cash (in Shares)

'

'

'

'

'

163,438

'

'

'

'

'

'

'

'

-163,438

Issuance of common stock upon release of restricted share units (in Shares)

'

'

'

'

'

60,500

'

'

'

'

'

'

'

'

'

Sale of

'

'

'

'

'

10,000

'

'

15,058,000

'

'

'

'

'

15,068,000

Sale of (in Shares)

'

'

'

'

'

9,652,335

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

'

'

'

'

'

'

'

'

875,000

'

'

'

'

'

875,000

Net loss

'

'

'

'

'

'

'

'

'

'

'

-13,575,000

'

'

-13,575,000

Net change in unrealized loss on marketable securities

'

'

'

'

'

'

'

'

'

'

-4,000

'

'

'

-4,000

Balance at June 30 at Jun. 30, 2012

'

'

'

'

'

37,000

'

'

149,348,000

-596,000

-5,000

-137,424,000

'

'

11,360,000

Balance at June 30 (in Shares) at Jun. 30, 2012

'

'

'

'

'

36,511,388

'

'

'

'

'

'

'

'

'

Issuance of common stock upon exercise of employee stock options for cash

'

'

'

'

'

'

'

'

88,000

'

'

'

'

'

88,000

Issuance of common stock upon exercise of employee stock options for cash (in Shares)

'

'

'

'

'

10,518

'

'

'

'

'

'

'

'

-10,518

Issuance of common stock upon release of restricted share units (in Shares)

'

'

'

'

'

48,000

'

'

'

'

'

'

'

'

'

Sale of

'

'

14,000

'

'

'

13,998,000

729,000

'

'

'

'

14,012,000

729,000

'

Sale of (in Shares)

'

'

14,251,368

-166,759

414,099

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

'

'

'

'

'

'

'

'

922,000

'

'

'

'

'

922,000

Net loss

'

'

'

'

'

'

'

'

'

'

'

-16,137,000

'

'

-16,137,000

Balance at June 30 at Jun. 30, 2013

'

'

'

'

'

51,000

'

'

165,085,000

-596,000

-5,000

-153,561,000

'

'

10,974,000

Balance at June 30 (in Shares) at Jun. 30, 2013

'

'

'

'

'

51,068,614

'

'

'

'

'

'

'

'

'

Issuance of common stock upon release of restricted share units (in Shares)

'

'

'

'

'

122,666

'

'

'

'

'

'

'

'

'

Sale of

15,299,000

15,299,000

'

'

'

38,000

'

450,000

29,375,000

'

'

'

'

450,000

29,413,000

Sale of (in Shares)

191,474

'

'

'

439,163

37,375,000

'

'

'

'

'

'

'

'

'

Deemed dividend related to beneficial conversion feature of Series A preferred stock

1,915,000

'

'

'

'

'

'

'

-1,915,000

'

'

'

'

'

1,915,000

Stock-based compensation expense

'

'

'

'

'

'

'

'

1,020,000

'

'

'

'

'

1,020,000

Net loss

'

'

'

'

'

'

'

'

'

'

'

-16,966,000

'

'

-16,966,000

Net change in unrealized loss on marketable securities

'

'

'

'

'

'

'

'

'

'

-5,000

'

'

'

-5,000

Balance at June 30 at Jun. 30, 2014

$17,214,000

'

'

'

'

$89,000

'

'

$194,015,000

($596,000)

($10,000)

($170,527,000)

'

'

$40,185,000

Balance at June 30 (in Shares) at Jun. 30, 2014

191,474

'

'

'

'

89,005,443

'

'

'

'

'

'

'

'

'

Statements_of_Stockholders_Equ1

Statements of Stockholders' Equity (Parentheticals) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
	Convertible Preferred Stock [Member]	Wedbush [Member]	MLV [Member]	MLV [Member]
Stock financing costs	$1,000,000	$1,000,000	$51,000	$25,000

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Net loss	($16,966)	($16,137)	($13,575)
Adjustments to reconcile net loss to net cash used in operating activities	'	'	'
Depreciation and amortization of property and equipment	1,387	1,154	858
Amortization of premiums on marketable securities	126	135	'
Loss on disposal or retirement of property and equipment	60	68	102
Stock-based compensation expense on grants of stock awards to non-employees	107	65	134
Stock-based compensation expense on grants of stock awards to employees	913	857	741
Allowance for doubtful account	-33	33	'
Non cash interest expense	304	256	142
Changes in assets and liabilities	'	'	'
Accounts receivable	-282	-125	28
Prepaid expenses and other current assets	-96	-39	-54
Inventories	371	-881	264
Accounts payable and other accrued liabilities	171	-86	324
Accrued compensation	299	190	-120
Deferred revenue	-41	-336	1,276
Other non-current liabilities	-128	-19	162
Net cash used in operating activities	-13,808	-14,865	-9,718
Investing activities	'	'	'
Purchases of property and equipment	-822	-2,079	-2,550
Proceeds from maturities of investments	8,648	10,082	6,445
Purchases of investments	-40,158	-10,066	-11,129
Net cash used in investing activities	-32,332	-2,063	-7,234
Financing activities	'	'	'
Proceeds from sales of convertible preferred stock, net of issuance costs	15,299	'	'
Proceeds from sales of common stock, net of issuance costs	29,863	14,741	15,068
Proceeds from issuance of (repayment of) notes payable	'	'	2,390
Proceeds from issuance of common stock pursuant to the exercise of stock options	'	88	134
Net cash provided by financing activities	45,162	14,829	17,592
Net increase (decrease) in cash and cash equivalents	-978	-2,099	640
Cash and cash equivalents at beginning of period	6,373	8,472	7,832
Cash and cash equivalents at end of period	5,395	6,373	8,472
Supplemental disclosure of cash flow information	'	'	'
Cash paid for interest	200	200	77
Supplemental disclosure of non-cash investing and financing information	'	'	'
Deemed dividend related to beneficial conversion feature of convertible preferred stock	$1,915	'	'

Note_1_Organization_and_Summar

Note 1 - Organization and Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Note 1. Organization and Summary of Significant Accounting Policies
	Organization
	Cardica, Inc. ( the “Company”) was incorporated in the state of Delaware on October 15, 1997, as Vascular Innovations, Inc. On November 26, 2001, the Company changed its name to Cardica, Inc. The Company is commercializing and developing a microcutter product line based on its proprietary “staple-on-a-strip” technology intended for use by thoracic, bariatric, colorectal and general surgeons. The microcutter product line consists of the currently commercially-available MicroCutter XCHANGE® 30, a cartridge based microcutter device with a 5 millimeter shaft diameter and a 30 millimeter staple line, and products in development, including the MicroCutter XCHANGE® 45, a cartridge based microcutter device with an 8 millimeter shaft and a 45 millimeter staple line, the MicroCutter FLEXCHANGE™ 30, a cartridge based microcutter device with a flexible shaft to facilitate endoscopic procedures requiring cutting and stapling, and the MicroCutter XPRESS® 45, a multi-fire endolinear microcutter device with a 45 millimeter staple line specifically designed for the bariatric and thoracic surgery markets.
	In March 2012, the Company completed the design verification for and applied Conformité Européenne, or the CE Mark, to the MicroCutter XCHANGE 30 and, in December 2012, began a controlled commercial launch of the MicroCutter XCHANGE 30 in Europe. The Company received from the United States Food and Drug Administration, or FDA, 510(k) clearance for the MicroCutter XCHANGE 30 and blue cartridge in January 2014, and for the white cartridge in February 2014, for use in multiple open or minimally-invasive surgical procedures for the transection, resection and/or creation of anastomoses in small and large intestine, as well as the transection of the appendix. The blue cartridge is for use in medium thickness tissue, and the white cartridge is for use in thin tissue. In March 2014, the Company made its first sale of the MicroCutter XCHANGE 30 in the United States. The Company also recently submitted the MicroCutter XCHANGE 30 blue and white cartridges application to Health Canada for regulatory approval of the MicroCutter XCHANGE 30 and, if the Company receives approval, anticipate launching it in Canada. In addition, in August 2013, the Company’s exclusive distributor in Japan, Century Medical, Inc., or Century, filed for regulatory approval of the MicroCutter XCHANGE 30 cartridges with the Pharmaceuticals and Medical Devices Agency in Japan and, upon approval, anticipates launching the MicroCutter XCHANGE 30 in Japan.
	To date, the Company generated revenues almost exclusively from the sale of automated anastomotic systems, and has generated minimal revenues from the commercial sales of the MicroCutter XCHANGE 30 since its  introduction in Europe in December 2012, and in the United States in March 2014.
	Liquidity
	The Company has incurred cumulative net losses of $170.5 million through June 30, 2014, negative cash flows from operating activities and expects to incur losses for the next several years. As of June 30, 2014, the Company had approximately $40.5 million of cash, cash equivalents and short-term investments, $2.3 million in long-term investments and $4.0 million of debt principal outstanding. The Company believes that its existing cash, cash equivalents, short-term and long-term investments, will be sufficient to meet its anticipated cash needs to enable the Company to conduct its business substantially as currently conducted for at least the next 12 months. The Company would be able to extend this time period to the extent that it decreases its planned expenditures, or raises additional capital.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) generally requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could materially differ from these estimates.
	Cash and Cash Equivalents
	The Company’s cash and cash equivalents are maintained in checking, money market and mutual fund investment accounts. The Company considers all highly liquid investments with maturities remaining on the date of purchase of three months or less to be cash equivalents.
	Accounts Receivable
	Accounts receivable consists of trade receivables and other receivables. Accounts receivable are recorded at net realizable value, which approximates fair value. The Company evaluates the collectability of accounts receivable on a case-by-case basis and makes adjustments to the bad debt reserve for expected losses. The Company considers factors such as ability to pay, bankruptcy, credit ratings, payment history and past-due status of the accounts. If circumstances related to customers change, estimates of recoverability would be further adjusted. For the fiscal year ended June 30, 2014, the Company recovered $33,000 of bad debt reserve that was recorded in the fiscal year ended June 30, 2013.
	Available-for-Sale Securities
	Available-for-sale securities consist primarily of corporate debt securities, commercial papers, and certificates of deposits, and, by the Company's investment policy, restrict exposure to any single corporate issuer by imposing concentration limits. Although maturities may extend beyond one year, it is management's intent that these securities are available for use in current operations.
	The Company held investments in marketable securities as of June 30, 2014 and 2013, with maturity dates of less than one year for short-term and greater than one year for long-term. The Company records its marketable securities at fair value and classifies them as available-for-sale. The cost of securities sold is based on the specific-identification method. Interest on securities classified as available-for-sale is included in interest income. Unrealized gains or losses on available-for-sale securities are classified as other comprehensive income or loss and reported as a separate component of stockholders’ equity until realized.
	When the resulting fair value is significantly below cost basis and/or the significant decline has lasted for an extended period of time, the Company performs an evaluation to determine whether the marketable equity security is other than temporarily impaired. The evaluation that the Company uses to determine whether a marketable equity security is other than temporarily impaired is based on the specific facts and circumstances present at the time of assessment, which include significant quantitative and qualitative assessments and estimates regarding credit ratings, collateralized support, the length of time and significance of a security’s loss position and intent and ability to hold a security to maturity or forecasted recovery.
	Investments are summarized as follows (in thousands):
		As of June 30, 2014
		Amortized			Gross			Gross				Fair Value
		Cost			Unrealized			Unrealized
					Gains			Losses
	Available-for-sale securities:
	Money market funds – Short-term	$	17,658		$	—		$	—			$	17,658
	Corporate debt securities – Short-term		14,434			—			(6	)			14,428
	Commercial paper - Short-term		3,000			—			—				3,000
	Corporate debt securities – Long-term		2,319			—			(4	)			2,315
	Total	$	37,411		$	—		$	(10	)		$	37,401
		As of June 30, 2013
		Amortized			Gross			Gross				Fair Value
		Cost			Unrealized			Unrealized
					Gains			Losses
	Available-for-sale securities:
	Corporate debt securities – Short-term	$	5,527		$	—		$	(5	)		$	5,522
	Commercial paper – Short-term		500			—			—				500
	Total	$	6,027		$	—		$	(5	)		$	6,022
	Restricted Cash
	Under an operating lease for its facility in Redwood City, California, the Company is required to maintain a letter of credit with a restricted cash balance at the Company’s bank. A certificate of deposit of $100,000 at June 30, 2014 and 2013, has been recorded as restricted cash in the accompanying balance sheets, related to the letter of credit (see Note 5).
	A certificate of deposit of $4,000 at June 30, 2014 and 2013, has been recorded as restricted cash in the accompanying balance sheets related to the deposit on the Company’s merchant credit card.
	Concentrations of Credit Risk and Certain Other Risks
	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments, long-term investments and accounts receivable. The Company places its cash, cash equivalents, short-term and long-term investments with high-credit quality financial institutions. The Company is exposed to credit risk in the event of default by the institutions holding the cash, cash equivalents, short-term and long-term investments to the extent of the amounts recorded on the balance sheet. The Company sells its products to hospitals in the U.S. and Europe and to distributors in Europe, Japan and Saudi Arabia that resell the products to hospitals. The Company does not require collateral to support credit sales. The Company has had insignificant credit losses to date.
	The following table illustrates total net revenue from the geographic location in which the Company’s customers are located and sales revenue by product line.
	Net revenue by geographic location:
		Fiscal Year Ended June 30,
		2014			2013			2012
	United States		45	%		53	%		59	%
	Japan		29	%		29	%		29	%
	Europe		26	%		17	%		12	%
	Rest of world		—			1	%		—
	Sales revenue by product line:
		Fiscal Year Ended June 30,
		2014			2013			2012
	Microcutter	$	488		$	176		$	—
	Cardiac (automated anastomotic systems)		3,017			2,917			3,274
	Total	$	3,505		$	3,093		$	3,274
	The following table illustrates concentrations of credit risk for the periods presented.
		Percent of Total Net										Percent of Total
		Revenue for										Accounts Receivable
		Fiscal Year Ended June 30,										as of June 30,
		2014			2013			2012				2014			2013
	Century Medical		29	%		29	%		29	%			35	%		33	%
	Herz-Und Diabeteszentrum		12	%		7	%		7	%			8	%		—
	As of June 30, 2014, 2013 and 2012, and for the years then ended, no other customer accounted for equal to or greater than 10% of net revenue or account receivable balances. The Company does not believe that accounts receivable from Century Medical and Herz-Und Diabeteszentrum represent a significant credit risk based on past collection experiences and the general creditworthiness of these customers.
The Company depends upon a number of key suppliers, including single source suppliers, the loss of which would materially harm the Company’s business. Single source suppliers are relied upon for certain components and services used in manufacturing the Company’s products. The Company does not have long-term contracts with any of the suppliers; rather, purchase orders are submitted for each order. Because long-term contracts do not exist, none of the suppliers are required to provide the Company any guaranteed minimum quantities.
Inventories
Inventories are recorded at the lower of cost or market on a first-in, first-out basis. The Company periodically assesses the recoverability of all inventories, including materials, work-in-process and finished goods, to determine whether adjustments for impairment are required. Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions. Further reduced demand may result in the need for additional inventory write-downs in the near term. Inventory write-downs are charged to cost of product sales and establish a lower cost basis for the inventory.
Property and Equipment
Property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the related assets, which are generally three to five years. Amortization of leasehold improvements is computed using the straight-line method over the shorter of the remaining lease term or the estimated useful life of the related assets. Upon sale or retirement of assets, the costs and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the statement of operations.
Impairment of Long-Lived Assets
The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is assessed using discounted cash flows. All long-lived assets are in the United States, and through June 30, 2014, there have been no indications of impairment; therefore, the Company has recorded no such losses.
Revenue Recognition
The Company recognizes revenue when four basic criteria are met: (1) persuasive evidence of an arrangement exists; (2) title has transferred; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. The Company uses contracts and customer purchase orders to determine the existence of an arrangement. The Company uses shipping documents and third-party proof of delivery to verify that title has transferred. The Company assesses whether the fee is fixed or determinable based upon the terms of the agreement associated with the transaction. To determine whether collection is probable, the Company assesses a number of factors, including past transaction history with the customer and the creditworthiness of the customer. If the Company determines that collection is not reasonably assured, then the recognition of revenue is deferred until collection becomes reasonably assured, which is generally upon receipt of payment.
The Company records product sales net of estimated product returns and discounts from the list prices for its products. The amounts of product returns and the discount amounts have not been material to date. The Company’s sales to distributors do not include price protection or product return rights, outside of standard warranties. The Company includes shipping and handling costs in cost of product sales.
Payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved subject to satisfaction of all revenue recognition criteria at that time. Revenue generated from license fees and performing development services are recognized when they are earned and non-refundable upon receipt, over the period of performance, or upon incurrence of the related development expenses in accordance with contractual terms, based on the actual costs incurred to date plus overhead costs for certain project activities. Amounts paid but not yet earned on a project are recorded as deferred revenue until such time as performance is rendered or the related development expenses, plus overhead costs for certain project activities, are incurred.
Research and Development
Research and development expenses consist of costs incurred for internally sponsored research and development, direct expenses, research-related overhead expenses, and costs incurred on development contracts. Research and development costs are charged to research and development expenses as incurred.
Clinical Trials
The Company accrues and expenses costs for clinical trial activities performed by third parties based upon estimates of the percentage of work completed over the life of the individual study in accordance with agreements established with contract research organizations and clinical trial sites. The Company determines the estimates through discussion with internal clinical personnel and outside service providers as to progress or stage of completion of trials or services and the agreed upon fee to be paid for such services. Costs of setting up clinical trial sites for participation in the trials are expensed immediately as research and development expenses. Clinical trial site costs related to patient enrollment are accrued as patients are entered into the trial.
Deferred Rent
Rent expense is recognized on a straight-line basis over the non-cancelable term of the Company’s facility operating lease. The difference between the actual amounts paid and amounts recorded as rent expense is recorded to deferred rent. The current portion of deferred rent is recorded as other accrued liabilities, while the non-current portion is recorded in non-current accrued liabilities.
Income Taxes
The Company utilizes the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax reporting bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.
The Company would classify interest and penalties related to uncertain tax positions in income tax expense, if applicable. There was no interest expense or penalties related to unrecognized tax benefits recorded through June 30, 2014.
Segments
The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting purposes. All of the Company’s operations are in the United States and all of its long-lived assets are maintained in the United States.
Net Loss per Share
Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period without consideration of potential common shares. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period less the dilutive potential common shares for the period determined using the treasury-stock method. For purposes of this calculation, options, warrants and underlying convertible preferred shares to purchase stock and unvested restricted stock awards are considered to be potential common shares and are only included in the calculation of diluted net loss per share when their effect is dilutive.
In the years the Preferred Stock was outstanding, the two-class method was used to calculate basic and diluted earnings (loss) per common share since it is a participating security under ASC 260 Earnings per Share. The two-class method is an earnings allocation formula that determines earnings per share for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. Under the two-class method, basic earnings (loss) per common share is computed by dividing net earnings (loss) attributable to common share after allocation of earnings to participating securities by the weighted-average number of common shares outstanding during the year. Diluted earnings (loss) per common share is computed using the more dilutive of the two-class method or the if-converted method. In periods of net loss, no effect is given to participating securities since they do not contractually participate in the losses of the Company.
The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except per share data):
	Fiscal Year Ended June 30,
	2014			2013			2012
Numerator:
Net loss	$	(16,966	)	$	(16,137	)	$	(13,575	)
Deemed dividend related to beneficial conversion feature of convertible preferred stock		(1,915	)		—			—
Net loss allocable to common stockholders	$	(18,881	)	$	(16,137	)	$	(13,575	)
Denominator:
Weighted-average shares outstanding allocable to common stockholders		58,395			40,842			30,547
Denominator for basic and diluted net loss per share allocable to common stockholders		58,395			40,842			30,547
Basic and diluted net loss per share allocable to common stockholders	$	(0.32	)	$	(0.40	)	$	(0.44	)
The following table sets forth the outstanding securities not included in the diluted net loss per common share calculation for the fiscal years ended June 30, 2014 and 2013, because their effect would be antidilutive (in thousands):
	As of June 30,
	2014			2013
Options to purchase common stock		5,601			3,936
Non-vested restricted stock units and awards		16			46
Shares reserved for issuance upon conversion of Series A Preferred		19,147			—
Warrants		3,991			3,991
		28,755			7,973
Stock-Based Compensation
Stock-based compensation expense related to employee and director share-based compensation plans, including stock options and restricted stock units, is measured on the grant date, based on the fair value-based measurement of the award and is recognized as an expense over the requisite service period which generally equals the vesting period of each grant. The Company recognizes compensation expense using the accelerated method and the Company accounts for the non-employee share-based grants pursuant to ASC 505-50, Equity Based Payments to Non-Employees.
The Company selected the Black-Scholes option pricing model for determining the estimated fair value-based measurements of share-based awards. The use of the Black-Scholes model requires the use of assumptions including expected term, expected volatility, risk-free interest rate and expected dividends. The Company used the following assumptions in its fair value-based measurements:
	Fiscal Year Ended June 30,
	2014				2013				2012
Risk-free interest rate	0.91% – 1.49%				0.44% – 0.74%				0.58% – 0.83%
Dividend yield		—				—				—
Weighted-average expected life (in years)	3.8 – 4.6				3.8 – 4.6				3.8 – 4.6
Volatility	66% – 80 %				78% – 88 %				86% – 93 %
The Company estimates the expected life of options granted based on historical exercise and post-vest cancellation patterns, which the Company believes are representative of future behavior. The risk-free interest rate for the expected term of each option is based on a risk-free zero-coupon spot interest rate at the time of grant. The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. The expected volatility is based on the Company’s historical stock price. The Company estimates forfeitures in calculating the expense related to stock-based compensation. The Company recorded stock-based compensation expenses under ASC 718 of $0.9 million, or $0.02 per share, $0.9 million, or $0.02 per share, and $0.7 million, or $0.02 per share for the fiscal years ended June 30, 2014, 2013 and 2012, respectively. The Company recorded stock-based compensation expenses under ASC 505-50 of $0.1 million, or $0 per share for fiscal years ended June 30, 2014, 2013 and 2012.
Total compensation expense related to unvested awards not yet recognized is approximately $0.6 million at June 30, 2014, and is expected to be recognized over a weighted average period of 3.6 years.
Included in the statement of operations is the following non-cash stock-based compensation expense for the periods reported, including non-employee stock based compensation expense and the amortization of deferred compensation (in thousands):
	Fiscal Year Ended June 30,
	2014			2013			2012
Cost of product sales	$	117		$	88		$	82
Research and development		133			236			162
Selling, general and administrative		770			598			631
Total	$	1,020		$	922		$	875
Recent Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606): Revenue from Contracts with Customers, which guidance in this update will supersede the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance when it becomes effective. ASU No. 2014-09 affects any entity that enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards. The core principal of ASU No. 2014-09 is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU No. 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period, which will be the Company’s fiscal year 2018 (or July 1, 2017), and entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. Early adoption is prohibited. The Company will be evaluating the impact of the adoption of this guidance on the Company’s financial statements.
In July 2013, the FASB issued an accounting standard update which states that an unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed. In situations where a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction or the tax law of the jurisdiction does not require, and the entity does not intend to use the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The guidance will be effective prospectively for reporting periods beginning after December 15, 2013. The Company does not expect the adoption of this guidance to have a material impact on the Company’s financial statements.
In March 2013, the FASB issued an accounting standard update which requires the release of cumulative translation adjustments into net income when an entity ceases to have a controlling financial interest resulting in the complete or substantially complete liquidation of a subsidiary or group of assets within a foreign entity. The guidance will be effective prospectively for reporting periods beginning after December 15, 2013. The Company does not expect the adoption of this guidance to have a material impact on the Company’s financial statements.
In February 2013, the FASB issued amended standards to improve the reporting of reclassifications out of accumulated other comprehensive income by requiring an entity to report their corresponding effect(s) on net income. These amended standards are effective for annual reporting periods beginning after December 15, 2012. The Company adopted this guidance in July 2013, and it did not have a material impact on the Company’s financial statements for the fiscal year ended June 30, 2014.

Note_2_Fair_Value_Measurements

Note 2 - Fair Value Measurements	12 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	Note 2. Fair Value Measurements
	FASB Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures,” defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The three levels of inputs used to measure fair value are as follows:
	Level 1 — Quoted prices in active markets for identical assets or liabilities.
	Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
	Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company does not have any liabilities that are measured at fair value on a recurring basis. All assets that are measured at fair value on a recurring basis have been segregated into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date. These assets measured at fair value are summarized below (in thousands):
		As of June 30, 2014
		Level 1		Level 2		Level 3		Total
	Cash equivalents:
	Money market funds	$	2,500	$	—	$	—	$	2,500
	Short-term investments:
	Money market funds		17,658		—		—		17,658
	Corporate debt securities		—		14,428		—		14,428
	Commercial paper				3,000		—		3,000
	Long-term investments:
	Corporate debt securities		—		2,315		—		2,315
	Total assets at fair value	$	20,158	$	19,743	$	—	$	39,901
		As of June 30, 2013
		Level 1		Level 2		Level 3		Total
	Cash equivalents:
	Money market funds	$	5,462	$	—	$	—	$	5,462
	Short-term investments:
	Corporate debt securities		—		5,522		—		5,522
	Commercial paper		—		500		—		500
	Total assets at fair value	$	5,462	$	6,022	$	—	$	11,484
	Funds held in money market instruments, are included in Level 1 as their fair values are based on market prices/quotes for identical assets in active markets.
	Corporate debt securities and commercial papers are valued primarily using market prices comparable securities, bid/ask quotes, interest rate yields, and prepayment spreads and are included in Level 2.
	Cash balances of $2.9 million and $0.9 million at June 30, 2014 and 2013, respectively, are not included in the fair value hierarchy disclosure. As of June 30, 2014, the Company’s material financial assets and liabilities were reported at their current carrying values which approximate fair value given the short-term nature of less than a year, except for its note payable. As of June 30, 2014, the Company’s note payable was reported at its current carrying value which approximates fair value based on Level 3 unobservable inputs involving discounted cash flows and the estimated market rate of borrowing that could be obtained by companies with credit risk similar to the Company’s credit risk.

Note_3_Inventories

Note 3 - Inventories	12 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	Note 3. Inventories
	Inventories consisted of the following (in thousands):
		June 30,		June 30,
		2014		2013
	Raw materials	$	669	$	473
	Work in progress		207		594
	Finished goods		210		390
	Total	$	1,086	$	1,457

Note_4_Property_and_Equipment

Note 4 - Property and Equipment	12 Months Ended
	Jun. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	Note 4. Property and Equipment
	Property and equipment consisted of the following (in thousands):
		June 30,
		2014			2013
	Computer hardware and software	$	70		$	62
	Office furniture and equipment		27			27
	Machinery and equipment		6,306			5,916
	Leasehold improvements		174			174
			6,577			6,179
	Less: accumulated depreciation and amortization		(4,215	)		(3,079	)
	Subtotal		2,362			3,100
	Construction in process (1)		174			61
	Total	$	2,536		$	3,161
	(1) Construction in process includes equipments paid based on installment plan, but not yet placed in service pending completion. The completion dates for these equipments range from three months to two years, and the future payments are immaterial.

Note_5_Commitments_and_Conting

Note 5 - Commitments and Contingencies	12 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 5. Commitments and Contingencies
	On November 11, 2010, the Company entered into an amendment to its facility lease (the “Lease Amendment”). Pursuant to the Lease Amendment, the term of the lease was extended by four years, through August 31, 2015, and the Company was granted an improvement allowance of $148,070 to be used in connection with the construction of alterations and refurbishment of improvements in the premises, which was used and reimbursed in the fiscal year ended June 30, 2012. The leasehold improvement allowance will be recorded as a reduction of rent expense on a straight-line basis over the term of the lease. In addition, under the Lease Amendment, the Company was granted an option to further extend the lease for a period of two years beyond August 31, 2015 (the “Option Term”), with the annual rent payable by the Company during the Option Term to be equal to the annual rent for comparable buildings, as described in the Lease Amendment. Under the operating lease, the Company is required to maintain a letter of credit with a restricted cash balance at the Company’s bank. A certificate of deposit of $100,000 was recorded as restricted cash in the condensed balance sheets as of June 30, 2014 and 2013, related to the letter of credit.
	Future minimum lease payments under the non-cancelable operating leases having initial terms of a year or more as of June 30, 2014, including the Lease Amendment, are as follows (in thousands):
	Fiscal year ending June 30,	Operating
		Leases
	2015		689
	2016		118
	Total minimum lease payments	$	807
	Rent expense for fiscal years 2014, 2013 and 2012, was $0.6 million, $0.6 million and $0.6 million, respectively.

Note_6_Distribution_License_De

Note 6 - Distribution, License, Development and Commercialization Agreements	12 Months Ended
	Jun. 30, 2014
Disclosure Text Block [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	Note 6. Distribution, License, Development and Commercialization Agreements
	Century
	On September 2, 2011, the Company signed a distribution agreement (the “Distribution Agreement”) with Century Medical, Inc. (“Century”) with respect to distribution of the Company’s planned microcutter products in Japan. Under the terms of a secured note purchase agreement, Century agreed to loan the Company an aggregate of up to $4.0 million, with principal due in September 30, 2016, subject to certain conditions, which principal due date was extended by two years effective July 1, 2014. Under this facility, the Company received $2.0 million on September 30, 2011, and the remaining $2.0 million on December 27, 2011. The note bears 5% annual interest which is payable quarterly in arrears through September 30, 2018, the maturity date when the total $4.0 million of principal becomes due. In return for the loan commitment, the Company granted Century distribution rights to the Company’s planned microcutter product line in Japan, and a right of first negotiation for distribution rights in Japan to future products. Century will be responsible for securing regulatory approval from the Ministry of Health in Japan for the microcutter product line. After approval for marketing in Japan, the Company would sell microcutter units to Century, who would then sell the microcutter devices to their customers in Japan.
	Proceeds from the note and granting the distribution rights were allocated to the note based on its aggregate fair value of $2.4 million at the dates of receipt. This fair value was determined by discounting cashflows using a discount rate of 18%, which the Company estimated a market rate of borrowing that could be obtained by companies with credit risk similar to the Company’s. The remainder of the proceeds of $1.6 million was recognized as debt issuance discount and was allocated to the value of the distribution rights granted to Century under the Distribution Agreement and is included in deferred revenue. The deferred revenue will be recognized over the term of the Distribution Agreement, beginning upon the first sale by Century of the microcutter products in Japan.
	In addition, the distribution agreement with Century pertaining to the PAS-Port system, originally dated June 16, 2003, as amended, was last amended effective July 1, 2014. The last amendment, among other things, renewed the contract for another five years, extending the expiration date to July 31, 2019.
	Cook Incorporated
	In June 2007, the Company entered into, and in September 2007 and in June 2009 amended, a license, development and commercialization agreement with Cook, to develop and commercialize a specialized device, referred to as the PFO device, designed to close holes in the heart from genetic heart defects known as patent foramen ovales (“PFOs”). Under the agreement, Cook funded certain development activities and the Company and Cook jointly developed the device. The Company’s significant deliverables under the arrangement were the license rights and the associated development activities. These deliverables were determined to represent one unit of accounting as there was no standalone value to the license rights. If developed, Cook would receive an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, to make, have made, use, sell, offer for sale and import the PFO device. Under this agreement, the Company received no payments in the fiscal years ended June 30, 2014, 2013 and 2012. Amounts paid but not yet earned on the project are recorded as deferred revenue until such time as the related development expenses for certain project activities are incurred. A total of $0.4 million under this agreement has been recorded as deferred development revenue on the balance sheet as of June 30, 2014. On January 6, 2010, the Company and Cook mutually agreed to suspend work on the PFO project and, accordingly, the Company does not anticipate receiving any additional payments or recording any additional revenue related to this agreement in the foreseeable future.
	Intuitive Surgical
	On August 16, 2010, the Company entered into a license agreement with Intuitive Surgical Operations, Inc., or Intuitive Surgical, (the “License Agreement”) pursuant to which the Company granted to Intuitive Surgical a worldwide, sublicenseable, exclusive license to use the Company’s intellectual property in the robotics field in diagnostic or therapeutic medical procedures, but excluding vascular anastomosis applications, for an upfront license fee of $9.0 million. The Company is also eligible to receive a contingent payment related to achieving a certain sales volume. Each party has the right to terminate the License Agreement in the event of the other party’s uncured material breach or bankruptcy. Following any termination of the License Agreement, the licenses granted to Intuitive Surgical will continue, and except in the case of termination for the Company’s uncured material breach or insolvency, Intuitive Surgical’s payment obligations will continue as well. Under the License Agreement, Intuitive Surgical has rights to improvements in the Company’s technology and intellectual property over a specified period of time.
	The Company determined that there were two substantive deliverables under the License Agreement representing separate units of accounting: license rights to technology that existed as of August 16, 2010, and license rights to technology that may be developed over the following three years. The $9.0 million upfront license payment and $1.0 million premium on the stock purchase by Intuitive Surgical (see Note 8) were aggregated and allocated to the two units of accounting based upon the relative estimated selling prices of the deliverables. The relative estimated selling prices of the deliverables were determined using a probability weighted expected return model with significant inputs relating to the nature of potential future outcomes and the probability of occurrence of future outcomes. Based upon the relative estimated selling prices of the deliverables, $9.0 million of the total consideration of $10.0 million was allocated to the license rights to technology that existed as of August 16, 2010, that has been recognized as revenue in the fiscal year ended June 30, 2011, and $1.0 million was allocated to technology that may be developed over the following three years that is being recognized as revenue ratably over that three year period. In total, the revenue recognized for the fiscal years ended June 30, 2014, 2013 and 2012, related to this arrangement were $41,000, $0.3 million and $0.3 million, respectively. The Company has fully recognized such revenue, and as of June 30, 2014, no deferred revenue related to this arrangement.

Note_7_Note_Payable

Note 7 - Note Payable	12 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	Note 7. Notes Payable
	In connection with the Distribution Agreement with Century (see Note 6), the Company entered into a secured note purchase agreement and a related security agreement pursuant to which Century agreed to loan to the Company up to an aggregate of $4.0 million, which amount was received in the fiscal year ended June 30, 2012, and the secured note purchase agreement was amended effective July 1, 2014, to extend the principal due date by two years.  Under this facility, the Company received $2.0 million on September 30, 2011, and the remaining $2.0 million on December 27, 2011. This note bears 5% annual interest which is payable quarterly in arrears on the last business day of March, June, September and December of each year through September 30, 2018, the maturity date when the total $4.0 million of principal becomes due. The debt issuance discount of approximately $1.6 million is reflected as a reduction in long-term debt and is being amortized as interest expense over the term of the note using the effective interest method. The note is secured by substantially all of the Company's assets, including the Company’s intellectual property related to the PAS-Port® Proximal Anastomosis System, but excluding all other intellectual property, until the note is repaid. There are no covenants associated with this debt.
	The Company made interest payments of $200,000, $200,000 and $77,000 in the fiscal years ended June 30, 2014, 2013 and 2012, respectively. The interest payable at June 30, 2014 and 2013, was $50,000 and $50,000, respectively, and included in other accrued liabilities in the accompanying balance sheets.

Note_8_Stockholders_Equity

Note 8 - Stockholders' Equity	12 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 8. Stockholders’ Equity
	As of June 30, 2014, the total number of shares that the Company is authorized to issue is 130,000,000 shares, with 125,000,000 shares designated as common stock and 5,000,000 shares designated as preferred stock. As of June 30, 2013, the total number of shares that the Company was authorized to issue is 80,000,000 shares, with 75,000,000 shares designated as common stock and 5,000,000 shares designated as preferred stock.
	Common Stock
	Holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders of the Company. Subject to the preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by the Board of Directors. No dividends have been declared to date.
	In April 2014, the Company sold 37,375,000 shares of its common stock at $0.85 per share, and 191,474 shares of Series A Convertible Preferred Stock at $85 per share. The Series A convertible preferred stock is non-voting and is convertible into shares of its common stock at a conversion rate of 100 shares of common stock for each share of Series A convertible preferred stock, provided that conversion will be prohibited if, as a result, the holder and their affiliates would own more than 9.98% of the total number of shares of the Company’s common stock then outstanding unless the holder gives the Company at least 61 days prior notice of an intent to convert into shares of common stock that would cause the holder to own more than 9.98% of the total number of shares of common stock then issued and outstanding. Net proceeds from the financing to the Company were approximately $44.7 million. For fiscal year ended June 30, 2014, the Company recorded a deemed dividend of $1.9 million related to beneficial conversion feature of series A convertible preferred stock. A one-time beneficial conversion charge was due to the difference between the common stock price and conversion price on the closing date of the Company’s recently completed public offering.
	On March 20, 2013, the Company completed the sale of 14,251,368 shares of its common stock at a price to the public of $1.05 per share. Net proceeds from the financing to the Company were $14.0 million.
	In February 2012, the Company completed the sale of 9,091,000 shares of its common stock in an underwritten public offering at a price to the public of $1.65 per share. Net proceeds from that financing to us were $13.9 million.
	On August 3, 2011, the Company entered into the At The Market Issuance Sales Agreement (the “ATM Agreement”) with McNicoll, Lewis & Vlak LLC (“MLV”), which provided for the sale of the Company’s common stock through MLV as the Company’s sales agent. The ATM Agreement expired on August 2, 2014. As of June 30, 2014, the Company had received net proceeds of $1.2 million from the sale of an aggregate of 884,756 shares of common stock through MLV. During the fiscal years ended June 30, 2014 and 2013, the Company received net proceeds of $0.4 million and $0.7 million, respectively, from the sale of an aggregate of 439,163 and 414,099 shares of common stock through MLV, respectively.
	On August 16, 2010, the Company entered into a Stock Purchase Agreement with Intuitive Surgical pursuant to which Intuitive Surgical paid $3.0 million to purchase from the Company an aggregate of 1,249,541 newly-issued shares of the Company’s common stock (the “Stock Issuance”). The net proceeds recorded to stockholders’ equity based upon the fair value of the common stock on August 16, 2010, were approximately $2.0 million after offering expenses. See Note 6, Distribution, License, Development and Commercialization Agreements, for a discussion of the accounting treatment of the premium paid of $1.0 million, which is the amount Intuitive Surgical paid above the fair market value of the Company’s stock on the date of the agreement. There were no underwriters or placement agents involved with the Stock Issuance, and no underwriting discounts or commissions or similar fees were payable in connection with the Stock Issuance. Under the associated Registration Rights Agreement between the Company and Intuitive Surgical, the Company was required to meet certain obligations with respect to (1) filing a registration statement with the Securities and Exchange Commission pertaining to all common stock issued to Intuitive Surgical, and (2) using its reasonable best efforts to cause the registration statement to be declared effective within a specified number of days after filing the registration statement. The Company filed a registration statement related to the stock issued to Intuitive Surgical, and it was declared effective within the timeframes specified in the Registration Rights Agreement.
	On December 14, 2010, the Company entered into a common stock purchase agreement (the “Purchase Agreement”) with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which provided that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital was committed to purchase up to an aggregate of $10.0 million of shares of the Company’s common stock (the “Purchase Shares”) over the term of the Purchase Agreement at purchase prices determined in accordance with the Purchase Agreement. Pursuant to the Purchase Agreement, on any trading day on which the closing sale price of the Company’s common stock exceeded $1.00 per share, the Company had the right, in its sole discretion, to present Aspire Capital with a purchase notice, directing Aspire Capital to purchase up to (i) 100,000 shares of the Company’s common stock per trading day if the closing sale price of the Company’s common stock was above $1.00 per share, (ii) 200,000 shares of the Company’s common stock per trading day if the closing sale price of the Company’s common stock was above $2.25 per share and (iii) 300,000 shares of the Company’s common stock per trading day if the closing sale price of the Company’s common stock was above $3.50 per share. The purchase price per Purchase Share was to equal to the lesser of (i) the lowest sale price of the Company’s common stock on the purchase date or (ii) the arithmetic average of the three lowest closing sale prices for the Company’s common stock during the twelve consecutive trading days ending on the trading day immediately preceding the purchase date.
	In consideration for entering into the Purchase Agreement, concurrently with the execution of the Purchase Agreement, the Company issued to Aspire Capital 295,567 shares of the Company’s common stock as a commitment fee (the “Commitment Shares”). The value of the Commitment Shares of $966,000 and other costs related to entering into the Purchase Agreement of $134,000 represented financing costs that were recorded to additional paid-in capital upon capital being raised under the Purchase Agreement. The Purchase Agreement provided that the Company may not issue and sell more than 4,930,747 shares of the Company’s common stock, including the Commitment Shares.
	The Purchase Agreement terminated on February 10, 2013, and 166,759 shares of the Company’s common stock issued pursuant to the Purchase Agreement were returned to the Company as the maximum numbers of shares available under the Purchase Agreement were not sold to Aspire. Based on the quoted price, the shares were valued at $1.38 per share, or $230,000. The Company is no longer entitled to sell any further shares of its common stock to Aspire Capital under the Purchase Agreement. Through the termination date, a total of 1,478,808 shares of common stock (including the 128,808 Commitment Shares) had been issued to Aspire Capital pursuant to the Purchase Agreement and $4.4 million of capital had been raised through the sale of 1,350,000 shares of common stock at an average price of $3.23 per share.
	Preferred Stock
	The Company has 5,000,000 shares of authorized preferred stock issuable in one or more series. The Company can determine the number of shares constituting any series and the designation of such series and the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences and sinking fund terms, any or all of which may be greater than the rights of common stock. The issuance of the preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of the Company or other corporate action. As of June 30, 2014, the Company had designated 250,000 shares of preferred stock as series A convertible preferred stock, and there were 191,474 shares of series A convertible preferred stock issued and outstanding. There were no shares of preferred stock designated as series A convertible preferred stock or issued and outstanding as of June 30, 2013. For the fiscal year ended June 30, 2014, the Company recorded a deemed dividend of $1.9 million related to beneficial conversion feature of series A convertible preferred stock. A one-time beneficial conversion charge was due to the difference between the common stock price and conversion price on the closing date of the Company’s recently completed public offering.
	Each share of Series A preferred stock is convertible into 100 shares of the Company’s common stock at any time at the option of the holder, provided that the holder will be prohibited from converting Series A preferred stock into shares of the Company’s common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.98% of the total number of shares of the Company’s common stock then issued and outstanding, unless the holder gives us at least 61 days prior notice of an intent to convert into shares of common stock that would cause the holder to own more than 9.98% of the total number of shares of the Company’s common stock then issued and outstanding. In the event of the Company’s liquidation, dissolution, or winding up, holders of the Company’s Series A preferred stock will share ratably with the holders of the Company’s common stock on an as-if-converted basis. Shares of Series A preferred stock will generally have no voting rights, except as required by law and except that the consent of holders of a majority of the outstanding Series A Preferred Stock will be required to alter or change adversely the powers, preferences or rights given to the Series A preferred stock (an increase the number of authorized shares of Series A preferred stock shall not constitute an adverse change) or enter into any agreement to do so. Shares of Series A Preferred Stock will not be entitled to receive any dividends, unless a cash dividend is declared by the Company’s board of directors to be paid to the holders of common stock, in which case the holders of Series A Preferred Stock will be entitled to receive a cash dividend equal to the amount of dividends declared on the common stock on an as-if-converted basis.
	Shares Reserved
	Shares of common stock reserved for future issuance are as follows:
			June 30,
			2014
	Stock options and RSUs outstanding			5,617,479
	Shares available for grant under stock option plan			716,941
	Shares reserved for issuance upon conversion of Series A Preferred			19,147,400
	Warrants for common stock			3,991,205
				29,473,025
	Stock Options
	In 1997, the Company adopted the 1997 Equity Incentive Plan (the “1997 Plan”). The 1997 Plan provides for the granting of options to purchase common stock and the issuance of shares of common stock, subject to Company repurchase rights, to directors, employees and consultants. Certain options are immediately exercisable, at the discretion of the Board of Directors. Shares issued pursuant to the exercise of an unvested option are subject to the Company’s right of repurchase which lapses over periods specified by the board of directors, generally four years from the date of grant. In February 2006, the Company terminated all remaining unissued shares under the 1997 Plan. Although the 1997 Plan terminated, all outstanding options thereunder will continue to be governed by their existing terms.
	In October 2005, the Company’s Board of Directors adopted, and in December 2005 the stockholders approved, the 2005 Equity Incentive Plan, as amended (the “2005 Plan”). Pursuant to a series of amendments, a total of 6,400,000 shares of common stock have been reserved for issuance under the 2005 Plan as of June 30, 2014.
	Stock awards granted under the 2005 Plan may either be incentive stock options, nonstatutory stock options, stock bonuses or rights to acquire restricted stock. Incentive stock options may be granted to employees with exercise prices of no less than the fair value of the common stock on the date of grant, as determined by the Board of Directors, and nonstatutory options may be granted to employees, directors or consultants at exercise prices of no less than the fair value. If, at the time the Company grants an option, the awardee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, the option price shall be at least 110% of the fair value and shall not be exercisable more than five years after the date of grant. Options may be granted with vesting terms as determined by the Board of Directors. Options expire no more than 10 years after the date of grant, or earlier if employment is terminated.
	Common stock options may include a provision whereby the holder, while an employee, director or consultant, may elect at any time to exercise the option as to any part or all of the shares subject to the option prior to the full vesting of the option. Any unvested shares so purchased are subject to repurchase by the Company at its option and at a price equal to the original purchase price of the stock. The Company does not consider the stock issued upon exercise of an unvested stock option substantively exercised, and the cash paid for the exercise price is considered a deposit or a prepayment of the exercise price that is recognized by the Company as a liability. As the underlying shares vest, the deposit liability is reclassified as equity. As of June 30, 2014 and 2013, no such shares are subject to the Company’s right of repurchase and excluded from stockholders’ equity.
	Award activity under all Plans is as follows:
							Outstanding Options
			Shares				Number of				Weighted-
			Available for				Shares				Average
			Grant								Exercise
											Price Per
											Share
	Balance at June 30, 2011			837,304				3,381,738			$	2.59
	Shares reserved			750,000				—				—
	Restricted stock awards granted			(86,000	)			—				—
	Options granted			(899,400	)			899,400				2.13
	Options exercised			—				(163,438	)			2.01
	Options forfeited			263,529				(263,529	)			2.86
	Balance at June 30, 2012			865,433				3,854,171			$	2.53
	Shares reserved			750,000				—				—
	Restricted stock awards granted			(48,000	)			—				—
	Options granted			(671,150	)			671,150				1.53
	Options exercised			—				(10,518	)			1.31
	Options forfeited			578,908				(578,908	)			2.22
	Balance at June 30, 2013			1,475,191				3,935,895			$	2.43
	Shares reserved			1,000,000				—				—
	Restricted stock awards granted			(92,666	)			—				—
	Options granted			(1,944,500	)			1,944,500				1.24
	Options forfeited			278,916				(278,916	)			3.94
	Balance at June 30, 2014			716,941				5,601,479			$	1.95
	The following table summarizes information about options outstanding, vested and exercisable at June 30, 2014:
	Options Outstanding														Options exercisable
	Exercise Prices				Number of				Weighted-				Weighted		Number of		Weighted
					Shares				Average				Average		Shares		Average
									Remaining				Exercise				Exercise
									Contractual				Price per				Price per
									Life (years)				Share				Share
													$				$
	$0.99	–	$1.55			3,847,356				4.39				1.24		2,174,269		1.26
$1.56	–	$2.85			1,352,960				3.89				2.15		1,003,980		2.22
$2.86	–	$9.75			401,163				1.51				7.89		395,516		7.95
Total outstanding					5,601,479				4.06			$	1.95		3,573,765	$	2.28
Options vested and expected to vest					5,356,829				3.96			$	1.98
The weighted average remaining contractual life for all currently exercisable options as of June 30, 2014, was 2.9 years. The aggregate intrinsic value as of June 30, 2014, of all outstanding options was $105,000, options vested and expected to vest was $93,000 and options exercisable was $22,000. The aggregate intrinsic value as of June 30, 2013, of all outstanding options was $0, options vested and expected to vest was $0 and options exercisable was $0, as a result of the fair market value at June 30, 2013, being below the grant price ranges. The aggregate intrinsic value as of June 30, 2012, of all outstanding options was $1,116,000, options vested and expected to vest was $1,093,000 and options exercisable was $769,000.
The weighted-average estimated grant date fair value of options granted to employees and directors during fiscal years 2014, 2013 and 2012 was $0.80, $1.03 and $1.45 per share, respectively. The intrinsic value of all options exercised during fiscal years 2014, 2013 and 2012 was $0, $4,000 and $122,000, respectively. The fair value of all stock options actually vesting in fiscal years 2014, 2013 and 2012 was $528,000, $746,000 and $734,000, respectively.
Restricted Stock Units and Awards
The following table summarizes information about restricted stock activity.
		Shares
Non-vested restricted stock at June 30, 2011			20,500
Awarded			86,000
Vested			(60,500	)
Forfeited			—
Non-vested restricted stock at June 30, 2012			46,000
Awarded			48,000
Vested			(48,000	)
Forfeited			—
Non-vested restricted stock at June 30, 2013			46,000
Awarded			92,666
Vested			(122,666	)
Forfeited			—
Non-vested restricted stock at June 30, 2014			16,000
The aggregate intrinsic value as of June 30, 2014, of all non-vested restricted stock awards was $18,000, and awards expected to vest was $18,000.
The estimated grant date fair value of awards granted during fiscal years 2014, 2013 and 2012, was $1.15, $1.43 and $1.82 per share, respectively. The intrinsic value of all awards granted during fiscal years 2014, 2013 and 2012 was $106,000, $66,000 and $80,000, respectively. The fair value of all stock awards actually vesting in fiscal years 2014, 2013 and 2012 was $165,000, $75,000 and $73,000, respectively.
The fair value of each restricted stock award is estimated based upon the closing price of the Company’s common stock on the grant date. Share-based compensation expense related to restricted stock units and awards is recognized over the requisite service period as adjusted for estimated forfeitures.
Warrants
The Company has outstanding warrants to purchase common stock that are all exercisable at June 30, 2014, as follows:
	Shares				Exercise			Expiration
					Price Per
					Share
		3,991,205			$	1.45		Sep-14

Note_9_Income_Taxes

Note 9 - Income Taxes	12 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	Note 9. Income Taxes
	Deferred income taxes reflect the net tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows (in thousands):
		June 30,
		2014			2013
	Net operating loss carry-forwards	$	55,591		$	51,005
	Research credits		3,084			2,868
	Fixed asset depreciation		(109	)		(71	)
	Stock compensation		1,103			936
	Deferred revenue		158			806
	Other		764			617
	Total deferred tax assets		60,591			56,161
	Valuation allowance		(60,591	)		(56,161	)
	Net deferred tax assets	$	—		$	—
	Realization of the deferred tax assets is dependent upon future taxable income, the amount and timing of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The net valuation allowance increased by approximately $4.4 million, $6.8 million and $5.6 million during fiscal years ended June 30, 2014, 2013 and 2012, respectively.
	As of June 30, 2014, the Company had federal net operating loss carry-forwards and research credit carry-forwards of approximately $153.2 million and $1.5 million, respectively. The net operating loss carry-forwards begin to expire in the fiscal year 2019. The federal credits begin to expire in fiscal year 2021 if not utilized. Additionally, the Company’s state net operating loss carry-forwards of approximately $93.2 million begin to expire in the fiscal year 2015 and the Company has state research credit carry-forwards of $3.5 million. The California state credit carry-forwards have an unlimited carry-forward period and the State of Arizona credits begin to expire in fiscal year 2024.
	Included in the valuation allowance balance as of June 30, 2014, is $0.3 million related to the exercise of stock options which are not reflected as an expense for financial reporting purposes. Accordingly, any future reduction in the valuation allowance relating to this amount will be credited directly to equity and not reflected as an income tax benefit in the Statement of Operations.
	The reconciliation of income tax benefits attributable to the net loss computed at the U.S. federal statutory rates to the income tax benefit recorded (in thousands):
		Fiscal Year Ended June 30,
		2014			2013			2012
	Tax benefit at U.S. statutory rate	$	(5,768	)	$	(5,487	)	$	(4,648	)
	Loss for which no tax benefit is currently recognizable		5,584			5,341			4,502
	Stock based compensation		164			128			131
	Other, net		20			18			15
		$	—		$	—		$	—
	Utilization of the net operating loss carry-forwards and credit carry-forwards may be subject to a substantial annual limitation due to the limitations set forth in Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state provisions. In the fiscal year ended June 30, 2010, the Company completed a detailed analysis to determine whether an ownership change under Section 382 of the Internal Revenue Code had occurred. The effect of an ownership change would be the imposition of an annual limitation on the use of the net operating loss carry-forwards and credit carry-forwards attributable to periods before the change. Any subsequent ownership changes could further limit the use of net operating losses and credits. The Company concluded that approximately $4.9 million of federal net operating loss carry-forwards, $1.5 million of federal credit carry-forwards, and approximately $19.5 million of California state net operating loss carry-forwards are significantly limited to offset future income, if any. The reductions are reflected in the carry-forward amounts included above. The most recent analysis of the Company’s historical ownership changes was completed in 2014. Due to IRC Section 382 and 383 limitations, the Company only accounts for net operating loss and tax credit carryforwards as deferred tax assets where the Company reasonably expects that these losses and carryforwards can be utilized in future periods.
	At June 30, 2014, the Company had unrecognized tax benefits of $1.0 million, all of which would not currently affect the Company’s effective tax rate if recognized due to the Company’s deferred tax assets being fully offset by a valuation allowance. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):
		Amount
	Balance at June 30, 2012	$	756
	Additions based on tax positions related to current year		183
	Balance at June 30, 2013		939
	Additions based on tax positions related to current year		74
	Balance at June 30, 2014	$	1,013
	The Company would classify interest and penalties related to uncertain tax positions in income tax expense, if applicable. There was no interest expense or penalties related to unrecognized tax benefits recorded through June 30, 2014. The tax years 1998 through 2014 remain open to examination by one or more major taxing jurisdictions to which the Company is subject.

Note_10_Employee_Benefit_Plan

Note 10 - Employee Benefit Plan	12 Months Ended
	Jun. 30, 2014
Compensation and Retirement Disclosure [Abstract]	'
Pension and Other Postretirement Benefits Disclosure [Text Block]	'
	Note 10. Employee Benefit Plan
	In January 2001, the Company adopted a 401(k) Profit Sharing Plan that allows voluntary contributions by eligible employees. Employees may elect to contribute up to the maximum allowed under the Internal Revenue Service regulations. The Company may make discretionary contributions as determined by the Board of Directors. No amount was contributed by the Company to the plan during fiscal years ended June 30, 2014, 2013 or 2012.

Note_11_Indemnification

Note 11 - Indemnification	12 Months Ended
	Jun. 30, 2014
Indemnification [Text Block] [Abstract]	'
Indemnification [Text Block]	'
	Note 11. Indemnification
	From time to time, the Company enters into contracts that require the Company, upon the occurrence of certain contingencies, to indemnify parties against third-party claims. These contingent obligations primarily relate to (i) claims against the Company’s customers for violation of third-party intellectual property rights caused by the Company’s products; (ii) claims resulting from personal injury or property damage resulting from the Company’s activities or products; (iii) claims by the Company’s office lessor arising out of the Company’s use of the premises; and (iv) agreements with the Company’s officers and directors under which the Company may be required to indemnify such persons for liabilities arising out of their activities on behalf of the Company. Because the obligated amounts for these types of agreements usually are not explicitly stated, the overall maximum potential amount of these obligations cannot be reasonably estimated. No liabilities have been recorded for these obligations on the Company’s balance sheets as of June 30, 2014 or 2013, as there are no amounts currently estimable and probable of payment.

Note_12_Financial_Information_

Note 12 - Financial Information by Quarter	12 Months Ended
	Jun. 30, 2014
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Information [Text Block]	'
	Note 12. Financial Information by Quarter
	Financial Information by Quarter (unaudited)
	Fiscal Year 2014:
			1st Quarter			2nd Quarter			3rd Quarter			4th Quarter
			(In thousands, except per share data)
	Total net revenue		$	805		$	851		$	934		$	1,025
	Gross profit (loss) on product sales			(255	)		(219	)		(452	)		(339	)
	Net loss			(3,739	)		(4,172	)		(4,379	)		(4,676	)
	Net loss allocable to common stockholders			(3,739	)		(4,172	)		(4,379	)		(6,591	)
	Basic and diluted net loss per share allocable to common stockholders			(0.07	)		(0.08	)		(0.09	)		(0.08	)
	Shares used in computing basic and diluted net loss per share allocable to common stockholders			51,089			51,314			51,587			79,590
	Fiscal Year 2013:
			1st Quarter			2nd Quarter			3rd Quarter			4th Quarter
			(In thousands, except per share data)
	Total net revenue		$	885		$	874		$	868		$	872
	Gross profit (loss) on product sales			150			(195	)		(322	)		(144	)
	Net loss			(4,140	)		(4,192	)		(3,946	)		(3,859	)
	Basic and diluted net loss per common share			(0.11	)		(0.11	)		(0.10	)		(0.08	)
	Shares used in computing basic and diluted net loss per common share			36,723			36,951			38,633			51,060
		-1	Gross profit is computed as total net product sales less cost of product sales.

Note_13_Subsequent_Event

Note 13 - Subsequent Event	12 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 13. Subsequent Event
	On June 24, 2014, the Company and Century Medical, Inc. signed a fifth amendment pursuant to the Distribution Agreement pertaining to the PAS-Port system, originally dated June 16, 2003, as amended, which amendment was effective July 1, 2014. The amendment, among other things, renewed the contract for another five years, extending the expiration date to July 31, 2019. In addition, on June 24, 2014, the Company and Century also signed an amendment pursuant to the Secured Note Purchase Agreement dated September 2, 2011, extending the maturity date of the loan under that agreement by two years from September 30, 2016, to September 30, 2018.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Business Description and Basis of Presentation [Text Block]	'
	Organization
	Cardica, Inc. ( the “Company”) was incorporated in the state of Delaware on October 15, 1997, as Vascular Innovations, Inc. On November 26, 2001, the Company changed its name to Cardica, Inc. The Company is commercializing and developing a microcutter product line based on its proprietary “staple-on-a-strip” technology intended for use by thoracic, bariatric, colorectal and general surgeons. The microcutter product line consists of the currently commercially-available MicroCutter XCHANGE® 30, a cartridge based microcutter device with a 5 millimeter shaft diameter and a 30 millimeter staple line, and products in development, including the MicroCutter XCHANGE® 45, a cartridge based microcutter device with an 8 millimeter shaft and a 45 millimeter staple line, the MicroCutter FLEXCHANGE™ 30, a cartridge based microcutter device with a flexible shaft to facilitate endoscopic procedures requiring cutting and stapling, and the MicroCutter XPRESS® 45, a multi-fire endolinear microcutter device with a 45 millimeter staple line specifically designed for the bariatric and thoracic surgery markets.
	In March 2012, the Company completed the design verification for and applied Conformité Européenne, or the CE Mark, to the MicroCutter XCHANGE 30 and, in December 2012, began a controlled commercial launch of the MicroCutter XCHANGE 30 in Europe. The Company received from the United States Food and Drug Administration, or FDA, 510(k) clearance for the MicroCutter XCHANGE 30 and blue cartridge in January 2014, and for the white cartridge in February 2014, for use in multiple open or minimally-invasive surgical procedures for the transection, resection and/or creation of anastomoses in small and large intestine, as well as the transection of the appendix. The blue cartridge is for use in medium thickness tissue, and the white cartridge is for use in thin tissue. In March 2014, the Company made its first sale of the MicroCutter XCHANGE 30 in the United States. The Company also recently submitted the MicroCutter XCHANGE 30 blue and white cartridges application to Health Canada for regulatory approval of the MicroCutter XCHANGE 30 and, if the Company receives approval, anticipate launching it in Canada. In addition, in August 2013, the Company’s exclusive distributor in Japan, Century Medical, Inc., or Century, filed for regulatory approval of the MicroCutter XCHANGE 30 cartridges with the Pharmaceuticals and Medical Devices Agency in Japan and, upon approval, anticipates launching the MicroCutter XCHANGE 30 in Japan.
	To date, the Company generated revenues almost exclusively from the sale of automated anastomotic systems, and has generated minimal revenues from the commercial sales of the MicroCutter XCHANGE 30 since its  introduction in Europe in December 2012, and in the United States in March 2014.
Liquidity Disclosure [Policy Text Block]	'
	Liquidity
	The Company has incurred cumulative net losses of $170.5 million through June 30, 2014, negative cash flows from operating activities and expects to incur losses for the next several years. As of June 30, 2014, the Company had approximately $40.5 million of cash, cash equivalents and short-term investments, $2.3 million in long-term investments and $4.0 million of debt principal outstanding. The Company believes that its existing cash, cash equivalents, short-term and long-term investments, will be sufficient to meet its anticipated cash needs to enable the Company to conduct its business substantially as currently conducted for at least the next 12 months. The Company would be able to extend this time period to the extent that it decreases its planned expenditures, or raises additional capital.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) generally requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could materially differ from these estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents
	The Company’s cash and cash equivalents are maintained in checking, money market and mutual fund investment accounts. The Company considers all highly liquid investments with maturities remaining on the date of purchase of three months or less to be cash equivalents.
Receivables, Policy [Policy Text Block]	'
	Accounts Receivable
	Accounts receivable consists of trade receivables and other receivables. Accounts receivable are recorded at net realizable value, which approximates fair value. The Company evaluates the collectability of accounts receivable on a case-by-case basis and makes adjustments to the bad debt reserve for expected losses. The Company considers factors such as ability to pay, bankruptcy, credit ratings, payment history and past-due status of the accounts. If circumstances related to customers change, estimates of recoverability would be further adjusted. For the fiscal year ended June 30, 2014, the Company recovered $33,000 of bad debt reserve that was recorded in the fiscal year ended June 30, 2013.
Marketable Securities, Policy [Policy Text Block]	'
	Available-for-Sale Securities
	Available-for-sale securities consist primarily of corporate debt securities, commercial papers, and certificates of deposits, and, by the Company's investment policy, restrict exposure to any single corporate issuer by imposing concentration limits. Although maturities may extend beyond one year, it is management's intent that these securities are available for use in current operations.
	The Company held investments in marketable securities as of June 30, 2014 and 2013, with maturity dates of less than one year for short-term and greater than one year for long-term. The Company records its marketable securities at fair value and classifies them as available-for-sale. The cost of securities sold is based on the specific-identification method. Interest on securities classified as available-for-sale is included in interest income. Unrealized gains or losses on available-for-sale securities are classified as other comprehensive income or loss and reported as a separate component of stockholders’ equity until realized.
	When the resulting fair value is significantly below cost basis and/or the significant decline has lasted for an extended period of time, the Company performs an evaluation to determine whether the marketable equity security is other than temporarily impaired. The evaluation that the Company uses to determine whether a marketable equity security is other than temporarily impaired is based on the specific facts and circumstances present at the time of assessment, which include significant quantitative and qualitative assessments and estimates regarding credit ratings, collateralized support, the length of time and significance of a security’s loss position and intent and ability to hold a security to maturity or forecasted recovery.
	Investments are summarized as follows (in thousands):
		As of June 30, 2014
		Amortized			Gross			Gross				Fair Value
		Cost			Unrealized			Unrealized
					Gains			Losses
	Available-for-sale securities:
	Money market funds – Short-term	$	17,658		$	—		$	—			$	17,658
	Corporate debt securities – Short-term		14,434			—			(6	)			14,428
	Commercial paper - Short-term		3,000			—			—				3,000
	Corporate debt securities – Long-term		2,319			—			(4	)			2,315
	Total	$	37,411		$	—		$	(10	)		$	37,401
		As of June 30, 2013
		Amortized			Gross			Gross				Fair Value
		Cost			Unrealized			Unrealized
					Gains			Losses
	Available-for-sale securities:
	Corporate debt securities – Short-term	$	5,527		$	—		$	(5	)		$	5,522
	Commercial paper – Short-term		500			—			—				500
	Total	$	6,027		$	—		$	(5	)		$	6,022
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Restricted Cash
	Under an operating lease for its facility in Redwood City, California, the Company is required to maintain a letter of credit with a restricted cash balance at the Company’s bank. A certificate of deposit of $100,000 at June 30, 2014 and 2013, has been recorded as restricted cash in the accompanying balance sheets, related to the letter of credit (see Note 5).
	A certificate of deposit of $4,000 at June 30, 2014 and 2013, has been recorded as restricted cash in the accompanying balance sheets related to the deposit on the Company’s merchant credit card.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Concentrations of Credit Risk and Certain Other Risks
	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments, long-term investments and accounts receivable. The Company places its cash, cash equivalents, short-term and long-term investments with high-credit quality financial institutions. The Company is exposed to credit risk in the event of default by the institutions holding the cash, cash equivalents, short-term and long-term investments to the extent of the amounts recorded on the balance sheet. The Company sells its products to hospitals in the U.S. and Europe and to distributors in Europe, Japan and Saudi Arabia that resell the products to hospitals. The Company does not require collateral to support credit sales. The Company has had insignificant credit losses to date.
	The following table illustrates total net revenue from the geographic location in which the Company’s customers are located and sales revenue by product line.
	Net revenue by geographic location:
		Fiscal Year Ended June 30,
		2014			2013			2012
	United States		45	%		53	%		59	%
	Japan		29	%		29	%		29	%
	Europe		26	%		17	%		12	%
	Rest of world		—			1	%		—
	Sales revenue by product line:
		Fiscal Year Ended June 30,
		2014			2013			2012
	Microcutter	$	488		$	176		$	—
	Cardiac (automated anastomotic systems)		3,017			2,917			3,274
	Total	$	3,505		$	3,093		$	3,274
	The following table illustrates concentrations of credit risk for the periods presented.
		Percent of Total Net										Percent of Total
		Revenue for										Accounts Receivable
		Fiscal Year Ended June 30,										as of June 30,
		2014			2013			2012				2014			2013
	Century Medical		29	%		29	%		29	%			35	%		33	%
	Herz-Und Diabeteszentrum		12	%		7	%		7	%			8	%		—
	As of June 30, 2014, 2013 and 2012, and for the years then ended, no other customer accounted for equal to or greater than 10% of net revenue or account receivable balances. The Company does not believe that accounts receivable from Century Medical and Herz-Und Diabeteszentrum represent a significant credit risk based on past collection experiences and the general creditworthiness of these customers.
	The Company depends upon a number of key suppliers, including single source suppliers, the loss of which would materially harm the Company’s business. Single source suppliers are relied upon for certain components and services used in manufacturing the Company’s products. The Company does not have long-term contracts with any of the suppliers; rather, purchase orders are submitted for each order. Because long-term contracts do not exist, none of the suppliers are required to provide the Company any guaranteed minimum quantities.
Inventory, Policy [Policy Text Block]	'
	Inventories
	Inventories are recorded at the lower of cost or market on a first-in, first-out basis. The Company periodically assesses the recoverability of all inventories, including materials, work-in-process and finished goods, to determine whether adjustments for impairment are required. Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions. Further reduced demand may result in the need for additional inventory write-downs in the near term. Inventory write-downs are charged to cost of product sales and establish a lower cost basis for the inventory.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and Equipment
	Property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the related assets, which are generally three to five years. Amortization of leasehold improvements is computed using the straight-line method over the shorter of the remaining lease term or the estimated useful life of the related assets. Upon sale or retirement of assets, the costs and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the statement of operations.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	'
	Impairment of Long-Lived Assets
	The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is assessed using discounted cash flows. All long-lived assets are in the United States, and through June 30, 2014, there have been no indications of impairment; therefore, the Company has recorded no such losses.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	The Company recognizes revenue when four basic criteria are met: (1) persuasive evidence of an arrangement exists; (2) title has transferred; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. The Company uses contracts and customer purchase orders to determine the existence of an arrangement. The Company uses shipping documents and third-party proof of delivery to verify that title has transferred. The Company assesses whether the fee is fixed or determinable based upon the terms of the agreement associated with the transaction. To determine whether collection is probable, the Company assesses a number of factors, including past transaction history with the customer and the creditworthiness of the customer. If the Company determines that collection is not reasonably assured, then the recognition of revenue is deferred until collection becomes reasonably assured, which is generally upon receipt of payment.
	The Company records product sales net of estimated product returns and discounts from the list prices for its products. The amounts of product returns and the discount amounts have not been material to date. The Company’s sales to distributors do not include price protection or product return rights, outside of standard warranties. The Company includes shipping and handling costs in cost of product sales.
	Payments that are contingent upon the achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved subject to satisfaction of all revenue recognition criteria at that time. Revenue generated from license fees and performing development services are recognized when they are earned and non-refundable upon receipt, over the period of performance, or upon incurrence of the related development expenses in accordance with contractual terms, based on the actual costs incurred to date plus overhead costs for certain project activities. Amounts paid but not yet earned on a project are recorded as deferred revenue until such time as performance is rendered or the related development expenses, plus overhead costs for certain project activities, are incurred.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development
	Research and development expenses consist of costs incurred for internally sponsored research and development, direct expenses, research-related overhead expenses, and costs incurred on development contracts. Research and development costs are charged to research and development expenses as incurred.
Clinical Trials [Policy Text Block]	'
	Clinical Trials
	The Company accrues and expenses costs for clinical trial activities performed by third parties based upon estimates of the percentage of work completed over the life of the individual study in accordance with agreements established with contract research organizations and clinical trial sites. The Company determines the estimates through discussion with internal clinical personnel and outside service providers as to progress or stage of completion of trials or services and the agreed upon fee to be paid for such services. Costs of setting up clinical trial sites for participation in the trials are expensed immediately as research and development expenses. Clinical trial site costs related to patient enrollment are accrued as patients are entered into the trial.
Deferred Charges, Policy [Policy Text Block]	'
	Deferred Rent
	Rent expense is recognized on a straight-line basis over the non-cancelable term of the Company’s facility operating lease. The difference between the actual amounts paid and amounts recorded as rent expense is recorded to deferred rent. The current portion of deferred rent is recorded as other accrued liabilities, while the non-current portion is recorded in non-current accrued liabilities.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	The Company utilizes the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax reporting bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.
	The Company would classify interest and penalties related to uncertain tax positions in income tax expense, if applicable. There was no interest expense or penalties related to unrecognized tax benefits recorded through June 30, 2014.
Segment Reporting, Policy [Policy Text Block]	'
	Segments
	The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting purposes. All of the Company’s operations are in the United States and all of its long-lived assets are maintained in the United States.
Earnings Per Share, Policy [Policy Text Block]	'
	Net Loss per Share
	Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period without consideration of potential common shares. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period less the dilutive potential common shares for the period determined using the treasury-stock method. For purposes of this calculation, options, warrants and underlying convertible preferred shares to purchase stock and unvested restricted stock awards are considered to be potential common shares and are only included in the calculation of diluted net loss per share when their effect is dilutive.
	In the years the Preferred Stock was outstanding, the two-class method was used to calculate basic and diluted earnings (loss) per common share since it is a participating security under ASC 260 Earnings per Share. The two-class method is an earnings allocation formula that determines earnings per share for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. Under the two-class method, basic earnings (loss) per common share is computed by dividing net earnings (loss) attributable to common share after allocation of earnings to participating securities by the weighted-average number of common shares outstanding during the year. Diluted earnings (loss) per common share is computed using the more dilutive of the two-class method or the if-converted method. In periods of net loss, no effect is given to participating securities since they do not contractually participate in the losses of the Company.
	The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except per share data):
		Fiscal Year Ended June 30,
		2014			2013			2012
	Numerator:
	Net loss	$	(16,966	)	$	(16,137	)	$	(13,575	)
	Deemed dividend related to beneficial conversion feature of convertible preferred stock		(1,915	)		—			—
	Net loss allocable to common stockholders	$	(18,881	)	$	(16,137	)	$	(13,575	)
	Denominator:
	Weighted-average shares outstanding allocable to common stockholders		58,395			40,842			30,547
	Denominator for basic and diluted net loss per share allocable to common stockholders		58,395			40,842			30,547
	Basic and diluted net loss per share allocable to common stockholders	$	(0.32	)	$	(0.40	)	$	(0.44	)
	The following table sets forth the outstanding securities not included in the diluted net loss per common share calculation for the fiscal years ended June 30, 2014 and 2013, because their effect would be antidilutive (in thousands):
		As of June 30,
		2014			2013
	Options to purchase common stock		5,601			3,936
	Non-vested restricted stock units and awards		16			46
	Shares reserved for issuance upon conversion of Series A Preferred		19,147			—
	Warrants		3,991			3,991
			28,755			7,973
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation
	Stock-based compensation expense related to employee and director share-based compensation plans, including stock options and restricted stock units, is measured on the grant date, based on the fair value-based measurement of the award and is recognized as an expense over the requisite service period which generally equals the vesting period of each grant. The Company recognizes compensation expense using the accelerated method and the Company accounts for the non-employee share-based grants pursuant to ASC 505-50, Equity Based Payments to Non-Employees.
	The Company selected the Black-Scholes option pricing model for determining the estimated fair value-based measurements of share-based awards. The use of the Black-Scholes model requires the use of assumptions including expected term, expected volatility, risk-free interest rate and expected dividends. The Company used the following assumptions in its fair value-based measurements:
		Fiscal Year Ended June 30,
		2014				2013				2012
	Risk-free interest rate	0.91% – 1.49%				0.44% – 0.74%				0.58% – 0.83%
	Dividend yield		—				—				—
	Weighted-average expected life (in years)	3.8 – 4.6				3.8 – 4.6				3.8 – 4.6
	Volatility	66% – 80 %				78% – 88 %				86% – 93 %
	The Company estimates the expected life of options granted based on historical exercise and post-vest cancellation patterns, which the Company believes are representative of future behavior. The risk-free interest rate for the expected term of each option is based on a risk-free zero-coupon spot interest rate at the time of grant. The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. The expected volatility is based on the Company’s historical stock price. The Company estimates forfeitures in calculating the expense related to stock-based compensation. The Company recorded stock-based compensation expenses under ASC 718 of $0.9 million, or $0.02 per share, $0.9 million, or $0.02 per share, and $0.7 million, or $0.02 per share for the fiscal years ended June 30, 2014, 2013 and 2012, respectively. The Company recorded stock-based compensation expenses under ASC 505-50 of $0.1 million, or $0 per share for fiscal years ended June 30, 2014, 2013 and 2012.
	Total compensation expense related to unvested awards not yet recognized is approximately $0.6 million at June 30, 2014, and is expected to be recognized over a weighted average period of 3.6 years.
	Included in the statement of operations is the following non-cash stock-based compensation expense for the periods reported, including non-employee stock based compensation expense and the amortization of deferred compensation (in thousands):
		Fiscal Year Ended June 30,
		2014			2013			2012
	Cost of product sales	$	117		$	88		$	82
	Research and development		133			236			162
	Selling, general and administrative		770			598			631
	Total	$	1,020		$	922		$	875
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606): Revenue from Contracts with Customers, which guidance in this update will supersede the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance when it becomes effective. ASU No. 2014-09 affects any entity that enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards. The core principal of ASU No. 2014-09 is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU No. 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period, which will be the Company’s fiscal year 2018 (or July 1, 2017), and entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. Early adoption is prohibited. The Company will be evaluating the impact of the adoption of this guidance on the Company’s financial statements.
	In July 2013, the FASB issued an accounting standard update which states that an unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed. In situations where a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction or the tax law of the jurisdiction does not require, and the entity does not intend to use the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The guidance will be effective prospectively for reporting periods beginning after December 15, 2013. The Company does not expect the adoption of this guidance to have a material impact on the Company’s financial statements.
	In March 2013, the FASB issued an accounting standard update which requires the release of cumulative translation adjustments into net income when an entity ceases to have a controlling financial interest resulting in the complete or substantially complete liquidation of a subsidiary or group of assets within a foreign entity. The guidance will be effective prospectively for reporting periods beginning after December 15, 2013. The Company does not expect the adoption of this guidance to have a material impact on the Company’s financial statements.
	In February 2013, the FASB issued amended standards to improve the reporting of reclassifications out of accumulated other comprehensive income by requiring an entity to report their corresponding effect(s) on net income. These amended standards are effective for annual reporting periods beginning after December 15, 2012. The Company adopted this guidance in July 2013, and it did not have a material impact on the Company’s financial statements for the fiscal year ended June 30, 2014.

Note_1_Organization_and_Summar1

Note 1 - Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Schedule of Available-for-sale Securities Reconciliation [Table Text Block]	'
		As of June 30, 2014
		Amortized			Gross			Gross				Fair Value
		Cost			Unrealized			Unrealized
					Gains			Losses
	Available-for-sale securities:
	Money market funds – Short-term	$	17,658		$	—		$	—			$	17,658
	Corporate debt securities – Short-term		14,434			—			(6	)			14,428
	Commercial paper - Short-term		3,000			—			—				3,000
	Corporate debt securities – Long-term		2,319			—			(4	)			2,315
	Total	$	37,411		$	—		$	(10	)		$	37,401
		As of June 30, 2013
		Amortized			Gross			Gross				Fair Value
		Cost			Unrealized			Unrealized
					Gains			Losses
	Available-for-sale securities:
	Corporate debt securities – Short-term	$	5,527		$	—		$	(5	)		$	5,522
	Commercial paper – Short-term		500			—			—				500
	Total	$	6,027		$	—		$	(5	)		$	6,022
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	'
		Fiscal Year Ended June 30,
		2014			2013			2012
	United States		45	%		53	%		59	%
	Japan		29	%		29	%		29	%
	Europe		26	%		17	%		12	%
	Rest of world		—			1	%		—
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]	'
		Fiscal Year Ended June 30,
		2014			2013			2012
	Microcutter	$	488		$	176		$	—
	Cardiac (automated anastomotic systems)		3,017			2,917			3,274
	Total	$	3,505		$	3,093		$	3,274
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	'
		Percent of Total Net										Percent of Total
		Revenue for										Accounts Receivable
		Fiscal Year Ended June 30,										as of June 30,
		2014			2013			2012				2014			2013
	Century Medical		29	%		29	%		29	%			35	%		33	%
	Herz-Und Diabeteszentrum		12	%		7	%		7	%			8	%		—
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
		Fiscal Year Ended June 30,
		2014			2013			2012
	Numerator:
	Net loss	$	(16,966	)	$	(16,137	)	$	(13,575	)
	Deemed dividend related to beneficial conversion feature of convertible preferred stock		(1,915	)		—			—
	Net loss allocable to common stockholders	$	(18,881	)	$	(16,137	)	$	(13,575	)
	Denominator:
	Weighted-average shares outstanding allocable to common stockholders		58,395			40,842			30,547
	Denominator for basic and diluted net loss per share allocable to common stockholders		58,395			40,842			30,547
	Basic and diluted net loss per share allocable to common stockholders	$	(0.32	)	$	(0.40	)	$	(0.44	)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
		As of June 30,
		2014			2013
	Options to purchase common stock		5,601			3,936
	Non-vested restricted stock units and awards		16			46
	Shares reserved for issuance upon conversion of Series A Preferred		19,147			—
	Warrants		3,991			3,991
			28,755			7,973
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
		Fiscal Year Ended June 30,
		2014				2013				2012
	Risk-free interest rate	0.91% – 1.49%				0.44% – 0.74%				0.58% – 0.83%
	Dividend yield		—				—				—
	Weighted-average expected life (in years)	3.8 – 4.6				3.8 – 4.6				3.8 – 4.6
	Volatility	66% – 80 %				78% – 88 %				86% – 93 %
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
		Fiscal Year Ended June 30,
		2014			2013			2012
	Cost of product sales	$	117		$	88		$	82
	Research and development		133			236			162
	Selling, general and administrative		770			598			631
	Total	$	1,020		$	922		$	875

Note_2_Fair_Value_Measurements1

Note 2 - Fair Value Measurements (Tables)	12 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	'
		As of June 30, 2014
		Level 1		Level 2		Level 3		Total
	Cash equivalents:
	Money market funds	$	2,500	$	—	$	—	$	2,500
	Short-term investments:
	Money market funds		17,658		—		—		17,658
	Corporate debt securities		—		14,428		—		14,428
	Commercial paper				3,000		—		3,000
	Long-term investments:
	Corporate debt securities		—		2,315		—		2,315
	Total assets at fair value	$	20,158	$	19,743	$	—	$	39,901
		As of June 30, 2013
		Level 1		Level 2		Level 3		Total
	Cash equivalents:
	Money market funds	$	5,462	$	—	$	—	$	5,462
	Short-term investments:
	Corporate debt securities		—		5,522		—		5,522
	Commercial paper		—		500		—		500
	Total assets at fair value	$	5,462	$	6,022	$	—	$	11,484

Note_3_Inventories_Tables

Note 3 - Inventories (Tables)	12 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
		June 30,		June 30,
		2014		2013
	Raw materials	$	669	$	473
	Work in progress		207		594
	Finished goods		210		390
	Total	$	1,086	$	1,457

Note_4_Property_and_Equipment_

Note 4 - Property and Equipment (Tables)	12 Months Ended
	Jun. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
		June 30,
		2014			2013
	Computer hardware and software	$	70		$	62
	Office furniture and equipment		27			27
	Machinery and equipment		6,306			5,916
	Leasehold improvements		174			174
			6,577			6,179
	Less: accumulated depreciation and amortization		(4,215	)		(3,079	)
	Subtotal		2,362			3,100
	Construction in process (1)		174			61
	Total	$	2,536		$	3,161

Note_5_Commitments_and_Conting1

Note 5 - Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	Fiscal year ending June 30,	Operating
		Leases
	2015		689
	2016		118
	Total minimum lease payments	$	807

Note_8_Stockholders_Equity_Tab

Note 8 - Stockholders' Equity (Tables)	12 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Stock Options Roll Forward [Table Text Block]	'
			June 30,
			2014
	Stock options and RSUs outstanding			5,617,479
	Shares available for grant under stock option plan			716,941
	Shares reserved for issuance upon conversion of Series A Preferred			19,147,400
	Warrants for common stock			3,991,205
				29,473,025
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
							Outstanding Options
			Shares				Number of				Weighted-
			Available for				Shares				Average
			Grant								Exercise
											Price Per
											Share
	Balance at June 30, 2011			837,304				3,381,738			$	2.59
	Shares reserved			750,000				—				—
	Restricted stock awards granted			(86,000	)			—				—
	Options granted			(899,400	)			899,400				2.13
	Options exercised			—				(163,438	)			2.01
	Options forfeited			263,529				(263,529	)			2.86
	Balance at June 30, 2012			865,433				3,854,171			$	2.53
	Shares reserved			750,000				—				—
	Restricted stock awards granted			(48,000	)			—				—
	Options granted			(671,150	)			671,150				1.53
	Options exercised			—				(10,518	)			1.31
	Options forfeited			578,908				(578,908	)			2.22
	Balance at June 30, 2013			1,475,191				3,935,895			$	2.43
	Shares reserved			1,000,000				—				—
	Restricted stock awards granted			(92,666	)			—				—
	Options granted			(1,944,500	)			1,944,500				1.24
	Options forfeited			278,916				(278,916	)			3.94
	Balance at June 30, 2014			716,941				5,601,479			$	1.95
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
	Options Outstanding														Options exercisable
	Exercise Prices				Number of				Weighted-				Weighted		Number of		Weighted
					Shares				Average				Average		Shares		Average
									Remaining				Exercise				Exercise
									Contractual				Price per				Price per
									Life (years)				Share				Share
													$				$
	$0.99	–	$1.55			3,847,356				4.39				1.24		2,174,269		1.26
	$1.56	–	$2.85			1,352,960				3.89				2.15		1,003,980		2.22
	$2.86	–	$9.75			401,163				1.51				7.89		395,516		7.95
	Total outstanding					5,601,479				4.06			$	1.95		3,573,765	$	2.28
	Options vested and expected to vest					5,356,829				3.96			$	1.98
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	'
			Shares
	Non-vested restricted stock at June 30, 2011			20,500
	Awarded			86,000
	Vested			(60,500	)
	Forfeited			—
	Non-vested restricted stock at June 30, 2012			46,000
	Awarded			48,000
	Vested			(48,000	)
	Forfeited			—
	Non-vested restricted stock at June 30, 2013			46,000
	Awarded			92,666
	Vested			(122,666	)
	Forfeited			—
	Non-vested restricted stock at June 30, 2014			16,000
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
		Shares				Exercise			Expiration
						Price Per
						Share
			3,991,205			$	1.45		Sep-14

Note_9_Income_Taxes_Tables

Note 9 - Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
		June 30,
		2014			2013
	Net operating loss carry-forwards	$	55,591		$	51,005
	Research credits		3,084			2,868
	Fixed asset depreciation		(109	)		(71	)
	Stock compensation		1,103			936
	Deferred revenue		158			806
	Other		764			617
	Total deferred tax assets		60,591			56,161
	Valuation allowance		(60,591	)		(56,161	)
	Net deferred tax assets	$	—		$	—
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
		Fiscal Year Ended June 30,
		2014			2013			2012
	Tax benefit at U.S. statutory rate	$	(5,768	)	$	(5,487	)	$	(4,648	)
	Loss for which no tax benefit is currently recognizable		5,584			5,341			4,502
	Stock based compensation		164			128			131
	Other, net		20			18			15
		$	—		$	—		$	—
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	'
		Amount
	Balance at June 30, 2012	$	756
	Additions based on tax positions related to current year		183
	Balance at June 30, 2013		939
	Additions based on tax positions related to current year		74
	Balance at June 30, 2014	$	1,013

Note_12_Financial_Information_1

Note 12 - Financial Information by Quarter (Tables)	12 Months Ended
	Jun. 30, 2014													Jun. 30, 2013
Quarterly Financial Information Disclosure [Abstract]	'													'
Schedule of Quarterly Financial Information [Table Text Block]	'													'
		1st Quarter			2nd Quarter			3rd Quarter			4th Quarter				1st Quarter			2nd Quarter			3rd Quarter			4th Quarter
		(In thousands, except per share data)													(In thousands, except per share data)
	Total net revenue	$	805		$	851		$	934		$	1,025		Total net revenue	$	885		$	874		$	868		$	872
	Gross profit (loss) on product sales		(255	)		(219	)		(452	)		(339	)	Gross profit (loss) on product sales		150			(195	)		(322	)		(144	)
	Net loss		(3,739	)		(4,172	)		(4,379	)		(4,676	)	Net loss		(4,140	)		(4,192	)		(3,946	)		(3,859	)
	Net loss allocable to common stockholders		(3,739	)		(4,172	)		(4,379	)		(6,591	)	Basic and diluted net loss per common share		(0.11	)		(0.11	)		(0.10	)		(0.08	)
	Basic and diluted net loss per share allocable to common stockholders		(0.07	)		(0.08	)		(0.09	)		(0.08	)	Shares used in computing basic and diluted net loss per common share		36,723			36,951			38,633			51,060
	Shares used in computing basic and diluted net loss per share allocable to common stockholders		51,089			51,314			51,587			79,590

Note_1_Organization_and_Summar2

Note 1 - Organization and Summary of Significant Accounting Policies (Details) (USD $)

3 Months Ended

12 Months Ended

201 Months Ended

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2014

Note 1 - Organization and Summary of Significant Accounting Policies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Net Income (Loss) Attributable to Parent

($4,676,000)

($4,379,000)

($4,172,000)

($3,739,000)

($3,859,000)

($3,946,000)

($4,192,000)

($4,140,000)

($16,966,000)

($16,137,000)

($13,575,000)

$170,500,000

Cash, Cash Equivalents, and Short-term Investments

40,500,000

'

'

'

'

'

'

'

40,500,000

'

'

40,500,000

Long-term Investments

2,315,000

'

'

'

'

'

'

'

2,315,000

'

'

2,315,000

Debt Instrument, Face Amount

4,000,000

'

'

'

'

'

'

'

4,000,000

'

'

4,000,000

Allowance for Loan and Lease Loss, Recovery of Bad Debts

'

'

'

'

'

'

'

'

33,000

'

'

'

Restricted Cash and Cash Equivalents

104,000

'

'

'

104,000

'

'

'

104,000

104,000

'

104,000

Impairment of Long-Lived Assets Held-for-use

'

'

'

'

'

'

'

'

0

'

'

'

Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense

'

'

'

'

'

'

'

'

0

'

'

'

Number of Operating Segments

'

'

'

'

'

'

'

'

1

'

'

'

Allocated Share-based Compensation Expense

'

'

'

'

'

'

'

'

900,000

900,000

700,000

'

Share-based Compensation, Effect on Earnings Per Share

'

'

'

'

'

'

'

'

'$0.02

'$0.02

'$0.02

'

Allocated Share-based Compensation Expense, Non-employee

'

'

'

'

'

'

'

'

100,000

100,000

100,000

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized

'

'

'

'

'

'

'

'

'

'

600,000

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'

'

'

'

'

'

'

'

'3 years 219 days

'

'

'

Non-emplyee Compensation [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Note 1 - Organization and Summary of Significant Accounting Policies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation, Effect on Earnings Per Share

'

'

'

'

'

'

'

'

'$0

'$0

'$0

'

Certificates of Deposit [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Note 1 - Organization and Summary of Significant Accounting Policies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Restricted Cash and Cash Equivalents

100,000

'

'

'

100,000

'

'

'

100,000

100,000

'

100,000

Restricted Cash Credit Card [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Note 1 - Organization and Summary of Significant Accounting Policies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Restricted Cash and Cash Equivalents

$4,000

'

'

'

$4,000

'

'

'

$4,000

$4,000

'

$4,000

Minimum [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Note 1 - Organization and Summary of Significant Accounting Policies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Property, Plant and Equipment, Useful Life

'

'

'

'

'

'

'

'

'3 years

'

'

'

Maximum [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Note 1 - Organization and Summary of Significant Accounting Policies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Property, Plant and Equipment, Useful Life

'

'

'

'

'

'

'

'

'5 years

'

'

'

Note_1_Organization_and_Summar3

Note 1 - Organization and Summary of Significant Accounting Policies (Details) - Investments (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Available-for-sale securities:	'	'
Amortized Cost	$37,411	$6,027
Gross Unrealized Losses	-10	-5
Fair Value	37,401	6,022
Corporate Debt Securities [Member]	'	'
Available-for-sale securities:	'	'
Amortized Cost	14,434	5,527
Gross Unrealized Losses	-6	-5
Fair Value	14,428	5,522
Commercial Paper, Not Included with Cash and Cash Equivalents [Member]	'	'
Available-for-sale securities:	'	'
Amortized Cost	3,000	500
Fair Value	3,000	500
Corporate Bond Securities [Member]	'	'
Available-for-sale securities:	'	'
Amortized Cost	2,319	'
Gross Unrealized Losses	-4	'
Fair Value	2,315	'
Money Market Funds [Member]	'	'
Available-for-sale securities:	'	'
Amortized Cost	17,658	'
Fair Value	$17,658	'

Note_1_Organization_and_Summar4

Note 1 - Organization and Summary of Significant Accounting Policies (Details) - Net Revenue from Geographic Location	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
UNITED STATES	'	'	'
Note 1 - Organization and Summary of Significant Accounting Policies (Details) - Net Revenue from Geographic Location [Line Items]	'	'	'
Revenue percentage by location	45.00%	53.00%	59.00%
JAPAN	'	'	'
Note 1 - Organization and Summary of Significant Accounting Policies (Details) - Net Revenue from Geographic Location [Line Items]	'	'	'
Revenue percentage by location	29.00%	29.00%	29.00%
Europe [Member]	'	'	'
Note 1 - Organization and Summary of Significant Accounting Policies (Details) - Net Revenue from Geographic Location [Line Items]	'	'	'
Revenue percentage by location	26.00%	17.00%	12.00%
All Other Countries [Member]	'	'	'
Note 1 - Organization and Summary of Significant Accounting Policies (Details) - Net Revenue from Geographic Location [Line Items]	'	'	'
Revenue percentage by location	'	1.00%	'

Note_1_Organization_and_Summar5

Note 1 - Organization and Summary of Significant Accounting Policies (Details) - Sales Revenue by Product Line (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'
Product sales, net	$3,505	$3,093	$3,274
Microcutter [Member]	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'
Product sales, net	488	176	'
Cardiac [Member]	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'
Product sales, net	$3,017	$2,917	$3,274

Note_1_Organization_and_Summar6

Note 1 - Organization and Summary of Significant Accounting Policies (Details) - Concentration of Risk, by Risk Factor (Customer Concentration Risk [Member])	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Century Medical [Member] | Sales Revenue, Goods, Net [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration by customer	29.00%	29.00%	29.00%
Century Medical [Member] | Accounts Receivable [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration by customer	35.00%	33.00%	'
Herz-Und Diabeteszentrum [Member] | Sales Revenue, Goods, Net [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration by customer	12.00%	7.00%	7.00%
Herz-Und Diabeteszentrum [Member] | Accounts Receivable [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration by customer	8.00%	'	'

Note_1_Organization_and_Summar7

Note 1 - Organization and Summary of Significant Accounting Policies (Details) - Computation of Basic and Diluted Net Loss Per Share (USD $)

3 Months Ended

12 Months Ended

201 Months Ended

In Thousands, except Per Share data, unless otherwise specified

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2014

Numerator:

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

($4,676)

($4,379)

($4,172)

($3,739)

($3,859)

($3,946)

($4,192)

($4,140)

($16,966)

($16,137)

($13,575)

$170,500

Deemed dividend related to beneficial conversion feature of convertible preferred stock

'

'

'

'

'

'

'

'

-1,915

'

'

'

Net loss allocable to common stockholders

($6,591)

($4,379)

($4,172)

($3,739)

'

'

'

'

($18,881)

($16,137)

($13,575)

'

Denominator:

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average shares outstanding allocable to common stockholders (in Shares)

'

'

'

'

'

'

'

'

58,395

40,842

30,547

'

Denominator for basic and diluted net loss per share allocable to common stockholders (in Shares)

79,590

51,587

51,314

51,089

51,060

38,633

36,951

36,723

58,395

40,842

30,547

'

Basic and diluted net loss per share allocable to common stockholders (in Dollars per share)

($0.08)

($0.09)

($0.08)

($0.07)

($0.08)

($0.10)

($0.11)

($0.11)

($0.32)

($0.40)

($0.44)

'

Note_1_Organization_and_Summar8

Note 1 - Organization and Summary of Significant Accounting Policies (Details) - Antidilutive Securities Excluded from Computation of Earnings Per Share	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities	28,755	7,973
Equity Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities	5,601	3,936
Restricted Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities	16	46
Common Stock, Shares Reserved for Future Issuance [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities	19,147	'
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities	3,991	3,991

Note_1_Organization_and_Summar9

Note 1 - Organization and Summary of Significant Accounting Policies (Details) - Share-based Payment Award, Stock Options, Valuation Assumptions	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Minimum [Member]	'	'	'
Note 1 - Organization and Summary of Significant Accounting Policies (Details) - Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]	'	'	'
Risk-free interest rate	0.91%	0.44%	0.58%
Weighted-average expected life (in years)	'3 years 292 days	'3 years 292 days	'3 years 292 days
Volatility	66.00%	78.00%	86.00%
Maximum [Member]	'	'	'
Note 1 - Organization and Summary of Significant Accounting Policies (Details) - Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]	'	'	'
Risk-free interest rate	1.49%	0.74%	0.83%
Weighted-average expected life (in years)	'4 years 219 days	'4 years 219 days	'4 years 219 days
Volatility	80.00%	88.00%	93.00%

Recovered_Sheet1

Note 1 - Organization and Summary of Significant Accounting Policies (Details) - Non-cash Stock-based Compensation (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'
Allocated share-based compensation expense	$900	$900	$700
Cost of Sales [Member] | Noncash Stockbased Compensation [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'
Allocated share-based compensation expense	117	88	82
Research and Development Expense [Member] | Noncash Stockbased Compensation [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'
Allocated share-based compensation expense	133	236	162
Selling, General and Administrative Expenses [Member] | Noncash Stockbased Compensation [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'
Allocated share-based compensation expense	770	598	631
Noncash Stockbased Compensation [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'
Allocated share-based compensation expense	$1,020	$922	$875

Note_2_Fair_Value_Measurements2

Note 2 - Fair Value Measurements (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Millions, unless otherwise specified
Fair Value Disclosures [Abstract]	'	'
Cash	$2.90	$0.90

Note_2_Fair_Value_Measurements3

Note 2 - Fair Value Measurements (Details) - Fair Value Measurements (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Note 2 - Fair Value Measurements (Details) - Fair Value Measurements [Line Items]	'	'
Total assets at fair value	$39,901	$11,484
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Note 2 - Fair Value Measurements (Details) - Fair Value Measurements [Line Items]	'	'
Short-term investments	17,658	'
Money Market Funds [Member]	'	'
Note 2 - Fair Value Measurements (Details) - Fair Value Measurements [Line Items]	'	'
Short-term investments	17,658	'
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 2 - Fair Value Measurements (Details) - Fair Value Measurements [Line Items]	'	'
Short-term investments	14,428	5,522
Corporate debt securities	2,315	'
Corporate Debt Securities [Member]	'	'
Note 2 - Fair Value Measurements (Details) - Fair Value Measurements [Line Items]	'	'
Short-term investments	14,428	5,522
Corporate debt securities	2,315	'
Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 2 - Fair Value Measurements (Details) - Fair Value Measurements [Line Items]	'	'
Short-term investments	3,000	500
Commercial Paper [Member]	'	'
Note 2 - Fair Value Measurements (Details) - Fair Value Measurements [Line Items]	'	'
Short-term investments	3,000	500
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]	'	'
Note 2 - Fair Value Measurements (Details) - Fair Value Measurements [Line Items]	'	'
Cash equivalents	2,500	5,462
Fair Value, Inputs, Level 1 [Member]	'	'
Note 2 - Fair Value Measurements (Details) - Fair Value Measurements [Line Items]	'	'
Total assets at fair value	20,158	5,462
Fair Value, Inputs, Level 2 [Member]	'	'
Note 2 - Fair Value Measurements (Details) - Fair Value Measurements [Line Items]	'	'
Total assets at fair value	19,743	6,022
Money Market Funds [Member]	'	'
Note 2 - Fair Value Measurements (Details) - Fair Value Measurements [Line Items]	'	'
Cash equivalents	$2,500	$5,462

Note_3_Inventories_Details_Inv

Note 3 - Inventories (Details) - Inventories (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Inventories [Abstract]	'	'
Raw materials	$669	$473
Work in progress	207	594
Finished goods	210	390
Total	$1,086	$1,457

Note_4_Property_and_Equipment_1

Note 4 - Property and Equipment (Details) - Property and Equipment (USD $)	Jun. 30, 2014		Jun. 30, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'		'
Property, Plant and Equipment, Gross	$6,577		$6,179
Less: accumulated depreciation and amortization	-4,215		-3,079
Subtotal	2,362		3,100
Property, Plant and Equipment, Net	2,536		3,161
Computer Equipment [Member]	'		'
Property, Plant and Equipment [Line Items]	'		'
Property, Plant and Equipment, Gross	70		62
Office Equipment [Member]	'		'
Property, Plant and Equipment [Line Items]	'		'
Property, Plant and Equipment, Gross	27		27
Machinery and Equipment [Member]	'		'
Property, Plant and Equipment [Line Items]	'		'
Property, Plant and Equipment, Gross	6,306		5,916
Leasehold Improvements [Member]	'		'
Property, Plant and Equipment [Line Items]	'		'
Property, Plant and Equipment, Gross	174		174
Construction in Progress [Member]	'		'
Property, Plant and Equipment [Line Items]	'		'
Property, Plant and Equipment, Net	$174	[1]	$61	[1]
[1]	Construction in process includes equipments paid based on installment plan, but not yet placed in service pending completion. The completion dates for these equipments range from three months to two years, and the future payments are immaterial.

Note_5_Commitments_and_Conting2

Note 5 - Commitments and Contingencies (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Note 5 - Commitments and Contingencies (Details) [Line Items]	'	'	'
Leasehold Improvements, Gross	'	'	$148,070
Restricted Cash and Cash Equivalents	104,000	104,000	'
Operating Leases, Rent Expense	600,000	600,000	600,000
Restricted Cash Letter Of Credit [Member]	'	'	'
Note 5 - Commitments and Contingencies (Details) [Line Items]	'	'	'
Restricted Cash and Cash Equivalents	$100,000	$100,000	'

Note_5_Commitments_and_Conting3

Note 5 - Commitments and Contingencies (Details) - Future Minimum Lease Payments for Operating Leases (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Future Minimum Lease Payments for Operating Leases [Abstract]	'
2015	$689
2016	118
Total minimum lease payments	$807

Note_6_Distribution_License_De1

Note 6 - Distribution, License, Development and Commercialization Agreements (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Aug. 16, 2010	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Dec. 27, 2011	Sep. 30, 2011	Jun. 30, 2014	Dec. 31, 2011
			Cook Incorporated [Member]	Intuitive Surgical [Member]	Intuitive Surgical [Member]	Intuitive Surgical [Member]	Intuitive Surgical [Member]	Century Medical [Member]	Century Medical [Member]	Century Medical [Member]	Century Medical [Member]
Note 6 - Distribution, License, Development and Commercialization Agreements (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Notes Payable	'	'	'	'	'	'	'	'	'	$4,000,000	'
Proceeds from Secured Notes Payable	'	'	'	'	'	'	'	2,000,000	2,000,000	'	'
Debt Instrument, Interest Rate, Stated Percentage	'	'	'	'	'	'	'	5.00%	'	5.00%	'
Notes Payable, Fair Value Disclosure	'	'	'	'	'	'	'	'	2,400,000	'	'
Fair Value Inputs, Discount Rate	'	'	'	'	'	'	'	'	'	18.00%	'
Debt Instrument, Unamortized Discount	'	'	'	'	'	'	'	'	1,600,000	'	1,600,000
Deferred Revenue	'	'	400,000	'	'	'	'	'	'	'	'
Licenses Revenue	'	'	'	9,000,000	41,000	300,000	300,000	'	'	'	'
Common Stock Premium	'	'	'	1,000,000	'	'	'	'	'	'	'
Noncash or Part Noncash Divestiture, Amount of Consideration Received	'	'	'	10,000,000	'	'	'	'	'	'	'
Deferred Revenue, Current	$403,000	$444,000	'	'	$0	'	'	'	'	'	'

Note_7_Note_Payable_Details

Note 7 - Note Payable (Details) (Century Medical [Member], USD $)	0 Months Ended		12 Months Ended
	Dec. 27, 2011	Sep. 30, 2011	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2011
Century Medical [Member]	'	'	'	'	'	'
Note 7 - Note Payable (Details) [Line Items]	'	'	'	'	'	'
Notes Payable	'	'	$4,000,000	'	'	'
Proceeds from Secured Notes Payable	2,000,000	2,000,000	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	5.00%	'	5.00%	'	'	'
Debt Instrument, Unamortized Discount	'	1,600,000	'	'	'	1,600,000
Interest Expense, Debt	'	'	200,000	200,000	77,000	'
Interest Payable, Current	'	'	$50,000	$50,000	'	'

Note_8_Stockholders_Equity_Det

Note 8 - Stockholders' Equity (Details) (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

26 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

35 Months Ended

0 Months Ended

26 Months Ended

Mar. 20, 2013

Feb. 10, 2013

Apr. 30, 2014

Feb. 28, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Apr. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Aug. 16, 2010

Feb. 10, 2013

Mar. 20, 2013

Apr. 30, 2014

Feb. 28, 2012

Jun. 30, 2014

Jun. 30, 2012

Mar. 20, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Dec. 14, 2010

Dec. 14, 2010

Dec. 14, 2010

Jun. 30, 2014

Jun. 30, 2014

Aug. 16, 2010

Feb. 10, 2013

Dec. 14, 2010

Feb. 10, 2013

Dec. 14, 2010

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

When Stock Price Is Above 1 Dollar Per Share [Member]

When Stock Price Is Above 2 Dollars 25 Cents Per Share [Member]

When Stock Price Is Above 3 Dollars 50 Cents Per Share [Member]

Maximum [Member]

MLV [Member]

Intuitive Surgical [Member]

Aspire Capital [Member]

Aspire Capital [Member]

Aspire Capital [Member]

Aspire Capital [Member]

MLV [Member]

MLV [Member]

Intuitive Surgical [Member]

Aspire Capital [Member]

Maximum [Member]

Aspire Capital [Member]

Aspire Capital [Member]

Aspire Capital [Member]

Note 8 - Stockholders' Equity (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock, Shares Authorized (in Shares)

'

'

'

'

130,000,000

80,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares Authorized (in Shares)

'

'

'

'

125,000,000

75,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Authorized (in Shares)

'

'

'

'

5,000,000

5,000,000

'

'

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues (in Shares)

'

'

'

'

'

'

'

191,474

'

'

439,163

414,099

1,249,541

1,350,000

14,251,368

37,375,000

9,091,000

37,375,000

9,652,335

'

'

'

'

'

'

'

'

'

'

884,756

'

'

295,567

1,478,808

'

Share Price (in Dollars per share)

'

'

'

'

'

'

'

$85

'

'

'

'

'

$3.23

'

$0.85

$1.65

'

'

$1.05

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.38

'

Convertible Preferred Stock, Shares Issued upon Conversion (in Shares)

'

'

'

'

'

'

'

100

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Ownership Threshold, Preferred Stock Conversion

'

'

'

'

'

'

'

9.98%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance or Sale of Equity

'

'

$44,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends Payable

'

'

'

'

'

'

'

'

1,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Common Stock

14,000,000

'

'

13,900,000

29,863,000

14,741,000

15,068,000

'

'

'

400,000

700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,200,000

3,000,000

'

'

4,400,000

'

Stock Issued During Period, Value, New Issues

'

'

'

'

29,413,000

'

15,068,000

'

'

'

'

'

2,000,000

'

'

'

'

38,000

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

966,000

'

'

Common Stock Premium

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate Value of Shares Committed to Be Purchased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

Share Purchase Agreement Threshold Price Per Share (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1

$2.25

$3.50

'

'

'

'

'

'

'

Number of Shares that Must Be Purchased Per Purchase Agreement (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

200,000

300,000

'

'

'

'

'

'

'

Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs

'

'

'

'

2,300,000

'

1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

134,000

'

'

Maximum Number of Shares that May Be Issued Under Purchase Agreement (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,930,747

Shares Returned to Company (in Shares) (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

166,759

'

'

'

Value of Shares Returned to Company

'

230,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Issued for Services (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

128,808

'

Preferred Stock, Shares Issued (in Shares)

'

'

'

'

191,474

0

'

'

191,474

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Outstanding (in Shares)

'

'

'

'

191,474

0

'

'

191,474

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)

'

'

'

'

6,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum Ownership Percentage Threshold for Increased Option Price

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of Option Price if Minimum Ownership Threshold is Met

'

'

'

'

110.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Option Term if Minimum Ownership Threshold is Met

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term

'

'

'

'

'4 years 21 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years 328 days

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value

'

'

'

'

105,000

0

1,116,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value

'

'

'

'

93,000

0

1,093,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18,000

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value

'

'

'

'

22,000

0

769,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

106,000

66,000

80,000

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)

'

'

'

'

$0.80

$1.03

$1.45

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.15

$1.43

$1.82

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value

'

'

'

'

0

4,000

122,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value

'

'

'

'

528,000

746,000

734,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

165,000

75,000

73,000

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$18,000

'

'

'

'

'

'

'

'

'

'

'

'

Note_8_Stockholders_Equity_Det1

Note 8 - Stockholders' Equity (Details) - Common Stock Reserved for Future Issuance	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Note 8 - Stockholders' Equity (Details) - Common Stock Reserved for Future Issuance [Line Items]	'	'	'	'
Stock options and RSUs outstanding	5,617,479	'	'	'
Shares available for grant under stock option plan	716,941	1,475,191	865,433	837,304
Warrants for common stock	3,991,205	'	'	'
	29,473,025	'	'	'
Series A Preferred Stock [Member]	'	'	'	'
Note 8 - Stockholders' Equity (Details) - Common Stock Reserved for Future Issuance [Line Items]	'	'	'	'
Shares reserved for issuance upon conversion of Series A Preferred	19,147,400	'	'	'

Note_8_Stockholders_Equity_Det2

Note 8 - Stockholders' Equity (Details) - Option Activity Under All Plans (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Note 8 - Stockholders' Equity (Details) - Option Activity Under All Plans [Line Items]	'	'	'	'
Shares Available for Grant	716,941	1,475,191	865,433	837,304
Number of Shares	5,601,479	3,935,895	3,854,171	3,381,738
Weighted-Average Exercise Price Per Share (in Dollars per share)	$1.95	$2.43	$2.53	$2.59
Shares Available for Grant	-1,944,500	-671,150	-899,400	'
Number of Shares	1,944,500	671,150	899,400	'
Weighted-Average Exercise Price Per Share (in Dollars per share)	$1.24	$1.53	$2.13	'
Number of Shares	'	-10,518	-163,438	'
Weighted-Average Exercise Price Per Share (in Dollars per share)	'	$1.31	$2.01	'
Shares Available for Grant	278,916	578,908	263,529	'
Number of Shares	-278,916	-578,908	-263,529	'
Weighted-Average Exercise Price Per Share (in Dollars per share)	$3.94	$2.22	$2.86	'
Employee Stock Option [Member]	'	'	'	'
Note 8 - Stockholders' Equity (Details) - Option Activity Under All Plans [Line Items]	'	'	'	'
Shares Available for Grant	1,000,000	750,000	750,000	'
Restricted Stock [Member]	'	'	'	'
Note 8 - Stockholders' Equity (Details) - Option Activity Under All Plans [Line Items]	'	'	'	'
Shares Available for Grant	-92,666	-48,000	-86,000	'

Note_8_Stockholders_Equity_Det3

Note 8 - Stockholders' Equity (Details) - Stock Options Outstanding, Vested and Exercisable (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'	'
Number of shares (in Shares)	5,601,479	3,935,895	3,854,171	3,381,738
Weighted-average remaining contractual life	'4 years 21 days	'	'	'
Weighted-average exercise price per share	$1.95	$2.43	$2.53	$2.59
Number of shares (in Shares)	3,573,765	'	'	'
Weighted-average exercise price per share	$2.28	'	'	'
(in Shares)	5,356,829	'	'	'
	'3 years 350 days	'	'	'
	$1.98	'	'	'
Range One [Member]	'	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'	'
Exercise price, lower range limit	$0.99	'	'	'
Exercise price, upper range limit	$1.55	'	'	'
Number of shares (in Shares)	3,847,356	'	'	'
Weighted-average remaining contractual life	'4 years 142 days	'	'	'
Weighted-average exercise price per share	$1.24	'	'	'
Number of shares (in Shares)	2,174,269	'	'	'
Weighted-average exercise price per share	$1.26	'	'	'
Range Two [Member]	'	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'	'
Exercise price, lower range limit	$1.56	'	'	'
Exercise price, upper range limit	$2.85	'	'	'
Number of shares (in Shares)	1,352,960	'	'	'
Weighted-average remaining contractual life	'3 years 324 days	'	'	'
Weighted-average exercise price per share	$2.15	'	'	'
Number of shares (in Shares)	1,003,980	'	'	'
Weighted-average exercise price per share	$2.22	'	'	'
Range Three [Member]	'	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'	'
Exercise price, lower range limit	$2.86	'	'	'
Exercise price, upper range limit	$9.75	'	'	'
Number of shares (in Shares)	401,163	'	'	'
Weighted-average remaining contractual life	'1 year 186 days	'	'	'
Weighted-average exercise price per share	$7.89	'	'	'
Number of shares (in Shares)	395,516	'	'	'
Weighted-average exercise price per share	$7.95	'	'	'

Note_8_Stockholders_Equity_Det4

Note 8 - Stockholders' Equity (Details) - Restricted Stock Activity (Restricted Stock [Member])	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Restricted Stock [Member]	'	'	'
Note 8 - Stockholders' Equity (Details) - Restricted Stock Activity [Line Items]	'	'	'
Non-vested restricted stock at June 30, 2011	46,000	46,000	20,500
Non-vested restricted stock at June 30	16,000	46,000	46,000
Awarded	92,666	48,000	86,000
Vested	-122,666	-48,000	-60,500
Forfeited	0	0	0

Note_8_Stockholders_Equity_Det5

Note 8 - Stockholders' Equity (Details) - Stockholders' Equity Note, Warrants or Rights (USD $)	Jun. 30, 2014
Stockholders' Equity Note, Warrants or Rights [Abstract]	'
	3,991,205
	$1.45

Note_9_Income_Taxes_Details

Note 9 - Income Taxes (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Note 9 - Income Taxes (Details) [Line Items]	'	'	'
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$4,400,000	$6,800,000	$5,600,000
Operating Loss Carryforwards	153,200,000	'	'
Deferred Tax Assets, Tax Credit Carryforwards, Research	1,500,000	'	'
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	93,200,000	'	'
Deferred Tax Assets, Valuation Allowance	60,591,000	56,161,000	'
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	4,900,000	'	'
Deferred Tax Assets, Tax Credit Carryforwards	1,500,000	'	'
Unrecognized Tax Benefits	1,013,000	939,000	756,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	0	'	'
State and Local Jurisdiction [Member]	'	'	'
Note 9 - Income Taxes (Details) [Line Items]	'	'	'
Deferred Tax Assets, Tax Credit Carryforwards, Research	3,500,000	'	'
Employee Stock Option [Member]	'	'	'
Note 9 - Income Taxes (Details) [Line Items]	'	'	'
Deferred Tax Assets, Valuation Allowance	300,000	'	'
California State [Member]	'	'	'
Note 9 - Income Taxes (Details) [Line Items]	'	'	'
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	$19,500,000	'	'

Note_9_Income_Taxes_Details_De

Note 9 - Income Taxes (Details) - Deferred Tax Assets (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Deferred Tax Assets [Abstract]	'	'
Net operating loss carry-forwards	$55,591	$51,005
Research credits	3,084	2,868
Fixed asset depreciation	-109	-71
Stock compensation	1,103	936
Deferred revenue	158	806
Other	764	617
Total deferred tax assets	60,591	56,161
Valuation allowance	-60,591	-56,161
Net deferred tax assets	$0	$0

Note_9_Income_Taxes_Details_Ef

Note 9 - Income Taxes (Details) - Effective Income Tax Rate Reconciliation (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Effective Income Tax Rate Reconciliation [Abstract]	'	'	'
Tax benefit at U.S. statutory rate	($5,768)	($5,487)	($4,648)
Loss for which no tax benefit is currently recognizable	5,584	5,341	4,502
Stock based compensation	164	128	131
Other, net	20	18	15
	$0	$0	$0

Note_9_Income_Taxes_Details_Un

Note 9 - Income Taxes (Details) - Unrecognized Tax Benefits (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Unrecognized Tax Benefits [Abstract]	'	'	'
Balance at June 30	$1,013	$939	$756
Additions based on tax positions related to current year	$74	$183	'

Note_10_Employee_Benefit_Plan_

Note 10 - Employee Benefit Plan (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Compensation and Retirement Disclosure [Abstract]	'	'	'
Defined Contribution Plan, Employer Discretionary Contribution Amount	$0	$0	$0

Note_12_Financial_Information_2

Note 12 - Financial Information by Quarter (Details) - Financial Information by Quarter (Unaudited), Fiscal Year 2014 (USD $)	3 Months Ended								12 Months Ended			201 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2014
Financial Information by Quarter (Unaudited), Fiscal Year 2014 [Abstract]	'	'	'	'	'	'	'	'	'	'	'	'
Total net revenue	$1,025	$934	$851	$805	$872	$868	$874	$885	$3,615	$3,499	$3,681	'
Gross profit (loss) on product sales	-339	-452	-219	-255	-144	-322	-195	150	'	'	'	'
Net loss	-4,676	-4,379	-4,172	-3,739	-3,859	-3,946	-4,192	-4,140	-16,966	-16,137	-13,575	170,500
Net loss allocable to common stockholders	($6,591)	($4,379)	($4,172)	($3,739)	'	'	'	'	($18,881)	($16,137)	($13,575)	'
Basic and diluted net loss per share allocable to common stockholders (in Dollars per share)	($0.08)	($0.09)	($0.08)	($0.07)	($0.08)	($0.10)	($0.11)	($0.11)	($0.32)	($0.40)	($0.44)	'
Shares used in computing basic and diluted net loss per share allocable to common stockholders (in Shares)	79,590	51,587	51,314	51,089	51,060	38,633	36,951	36,723	58,395	40,842	30,547	'

Note_12_Financial_Information_3

Note 12 - Financial Information by Quarter (Details) - Financial Information by Quarter (Unaudited), Fiscal Year 2013 (USD $)	3 Months Ended								12 Months Ended			201 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2014
Financial Information by Quarter (Unaudited), Fiscal Year 2013 [Abstract]	'	'	'	'	'	'	'	'	'	'	'	'
Total net revenue	$1,025	$934	$851	$805	$872	$868	$874	$885	$3,615	$3,499	$3,681	'
Gross profit (loss) on product sales	-339	-452	-219	-255	-144	-322	-195	150	'	'	'	'
Net loss	($4,676)	($4,379)	($4,172)	($3,739)	($3,859)	($3,946)	($4,192)	($4,140)	($16,966)	($16,137)	($13,575)	$170,500
Basic and diluted net loss per common share (in Dollars per share)	($0.08)	($0.09)	($0.08)	($0.07)	($0.08)	($0.10)	($0.11)	($0.11)	($0.32)	($0.40)	($0.44)	'
Shares used in computing basic and diluted net loss per common share (in Shares)	79,590	51,587	51,314	51,089	51,060	38,633	36,951	36,723	58,395	40,842	30,547	'